L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 2001:738916 CAPLUS
DN 135:242197
TI Regioselectivity of electrophilic attack on 4-methyl-1-thioxo-1,2,4,5-tetrahydro[1,2,4]triazolo[4,3-a]quinazolin-5-one. Part 2: Reactions on nitrogen atom
AU Fathalla, W.; Cajan, M.; Pazdera, P.
CS Department of Organic Chemistry, Faculty of Science, Masaryk University, Brno, Czech Rep.
SO Electronic Journal of Geotechnical Engineering [online computer file] (2000), 5, 1210-1223
CODEN: EJGEFK; ISSN: 1089-3032
URL: http://www.mdpi.org/molecules/papers/51201210.pdf
PB Electronic Journal of Geotechnical Engineering
DT Journal; (online computer file)
LA English
AB The regioselectivity of a cyclic thioamide group towards different electrophiles was studied on the title compd. (I). I reacts with alkyl halides, amines in the presence of formaldehyde, acyl halides and compds. having activated double bonds to afford the N-substituted derivs. The regioselective reactions on nitrogen atom are due to strong Coulombic attraction. The reaction of I with amines in the presence of hydrogen peroxide afforded the aminolysis products.
IT **361155-16-0P 361155-17-1P 361155-18-2P 361155-19-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(regioselectivity of electrophilic attack on 4-methyl-1-thioxo-1,2,4,5-tetrahydro[1,2,4]triazolo[4,3-a]quinazolin-5-one)
RN 361155-16-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 4-methyl-1-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 361155-17-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 4-methyl-1-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 361155-18-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 4-methyl-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 361155-19-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 4-methyl-1-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

App'S

L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 2000:790502 CAPLUS
DN 133:350240
TI 1-Aminotriazolo[4,3-a]quinazolin-5-ones and -5-thiones inhibiting phosphodiesterase IV
IN Gaudilliere, Bernard; Lavalette, Remi; Andrianjara, Charles; Breuzard, Francine
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 197 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000066584	A1	20001109	WO 2000-FR1174	20000428
	W: AE, AG, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2792938	A1	20001103	FR 1999-5398	19990428
	FR 2792938	B1	20010706		
	BR 2000010072	A	20020205	BR 2000-10072	20000428
	EP 1177195	A1	20020206	EP 2000-967407	20000428
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002543199	T2	20021217	JP 2000-615614	20000428
	NO 2001005235	A	20011221	NO 2001-5235	20011026
PRAI	FR 1999-5398	A	19990428		
	WO 2000-FR1174	W	20000428		

OS MARPAT 133:350240
GI



I



II

AB Triazolo[4,3-a]quinazolin-5-ones and -5-thiones I and II [A1 = O, S; X1, X2 = H, OH, halogen, amino, NO2, SH, CN, alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, (un)substituted CO2H; R = (un)substituted alkyl, alkenyl, alkynyl, pyridylalkyl; R1, R2 = alkyl, aralkyl, cycloalkyl, cycloalkylalkyl; NR1R2 = heterocyclic] were prepd. for use as inhibitors of phosphodiesterase IV. Thus, I [A = O, R = (E)-cinnamyl, X1 = 7-Cl, X2 = H, NR1R2 = perhydroazepino, III] was obtained together with II [A = O, R = (E)-cinnamyl, X1 = 7-Cl, X2 = H, NR1R2 = perhydroazepino] by treating I [A = O, R = H, X1 = 7-Cl, X2 = H, NR1R2 = perhydroazepino] with (E)-cinnamyl bromide. III had an IC50 for PDE-4 inhibition of 0.054 .mu.M.

IT **305802-88-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic

preparation); THU(Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT(Reactant or reagent); USES (Uses)
(1-aminotriazolo[4,3-a]quinazolin-5-ones and -5-thiones inhibiting phosphodiesterase IV)

RN 305802-88-4 CAPLUS

CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-[(4-nitrophenyl)methyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



IT **305802-41-9P 305802-43-1P 305802-51-1P**
305802-53-3P 305802-60-2P 305802-62-4P
305802-72-6P 305802-74-8P 305802-75-9P
305802-77-1P 305802-80-6P 305802-81-7P
305802-82-8P 305802-83-9P 305802-84-0P
305802-86-2P 305802-87-3P 305802-89-5P
305802-90-8P 305802-91-9P 305802-92-0P
305802-97-5P 305802-99-7P 305803-00-3P
305803-01-4P 305803-02-5P 305803-15-0P
305803-16-1P 305803-18-3P 305803-19-4P
305803-20-7P 305803-21-8P 305803-23-0P
305803-25-2P 305803-29-6P 305803-31-0P
305803-32-1P 305803-33-2P 305803-34-3P
305803-36-5P 305803-38-7P 305803-41-2P
305803-42-3P 305803-43-4P 305803-44-5P
305804-04-0P 305804-26-6P 305804-29-9P
305804-30-2P 305804-56-2P 305804-61-9P
305804-62-0P 305804-65-3P 305804-67-5P
305804-68-6P 305804-69-7P 305804-71-1P
305804-72-2P 305804-77-7P 305804-78-8P
305804-80-2P 305804-81-3P 305804-84-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(1-aminotriazolo[4,3-a]quinazolin-5-ones and -5-thiones inhibiting phosphodiesterase IV)

RN 305802-41-9 CAPLUS

CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-4-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)



RN 305802-43-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(dimethylamino)-4-[3-
(3-pyridinyl)-2-propenyl]- (9CI) (CA INDEX NAME)



RN 305802-51-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-4-[(4-
chlorophenyl)methyl]-1-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



RN 305802-53-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-4-[(4-
fluorophenyl)methyl]-1-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX

NAME)



RN 305802-60-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-4-[(3,4-dimethoxyphenyl)methyl]-1-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



RN 305802-62-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-4-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 305802-72-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-[(4-chlorophenyl)methyl]-1-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



RN 305802-74-8 CAPLUS
CN Benzonitrile, 4-[[7-bromo-1-(hexahydro-1H-azepin-1-yl)-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305802-75-9 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-[(3,4-dimethoxyphenyl)methyl]-1-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



RN 305802-77-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(hexahydro-1H-azepin-1-yl)-4-[(2E)-3-phenyl-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305802-80-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(hexahydro-1H-azepin-1-yl)-4-[(2E)-3-(3-pyridinyl)-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305802-81-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(hexahydro-1H-azepin-
1-yl)-4-[(2E)-3-(4-pyridinyl)-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305802-82-8 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-[(4-methylphenyl)methyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305802-83-9 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-[(4-chlorophenyl)methyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305802-84-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-[(4-fluorophenyl)methyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305802-86-2 CAPLUS
CN Benzonitrile, 4-[[7-bromo-5-oxo-1-(1-pyrrolidinyl)[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305802-87-3 CAPLUS
CN Benzoic acid, 4-[[7-bromo-5-oxo-1-(1-pyrrolidinyl)[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 305802-89-5 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-[(4-methoxyphenyl)methyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305802-90-8 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 4-[[4-(acetyloxy)phenyl]methyl]-7-bromo-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305802-91-9 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-[(4-hydroxyphenyl)methyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305802-92-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-[(3,4-dimethoxyphenyl)methyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305802-97-5 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-[(2E)-3-phenyl-2-propenyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305802-99-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-[(2E)-3-(4-chlorophenyl)-2-propenyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305803-00-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-[(2E)-3-(4-methoxyphenyl)-2-propenyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305803-01-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-[(2E)-3-(3-pyridinyl)-2-propenyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305803-02-5 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-[(2E)-3-(4-pyridinyl)-2-propenyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305803-15-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-[(3,4-dimethoxyphenyl)methyl]-1-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 305803-16-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-[(2E)-3-phenyl-2-propenyl]-1-(1-piperidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305803-18-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(dimethylamino)-4-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 305803-19-4 CAPLUS
CN Benzonitrile, 4-[[7-bromo-1-(dimethylamino)-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305803-20-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(dimethylamino)-4-[(4-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 305803-21-8 CAPLUS
CN Benzoic acid, 4-[[7-bromo-1-(dimethylamino)-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 305803-23-0 CAPLUS
CN Benzeneacetonitrile, 4-[[7-bromo-1-(dimethylamino)-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305803-25-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(dimethylamino)-4-[(2E)-3-phenyl-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305803-29-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(dimethylamino)-4-(3-phenyl-2-propynyl)- (9CI) (CA INDEX NAME)



RN 305803-31-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-(hexahydro-1H-azepin-1-yl)-7-
methyl-4-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 305803-32-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-(hexahydro-1H-azepin-1-yl)-7-
methyl-4-[(2E)-3-phenyl-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305803-33-2 CAPLUS
CN Benzonitrile, 4-[[7-methyl-5-oxo-1-(1-pyrrolidinyl)[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305803-34-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 4-[(3,4-dimethoxyphenyl)methyl]-7-methyl-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305803-36-5 CAPLUS
CN Benzeneacetic acid, 4-[[7-methyl-5-oxo-1-(1-pyrrolidinyl)[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305803-38-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-methyl-4-[(2E)-3-phenyl-2-propenyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305803-41-2 CAPLUS
CN Benzonitrile, 4-[[1-(dimethylamino)-7-methyl-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305803-42-3 CAPLUS
CN Benzeneacetic acid, 4-[[1-(dimethylamino)-7-methyl-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305803-43-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-(dimethylamino)-7-methyl-4-
[(2E)-3-phenyl-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305803-44-5 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-(dimethylamino)-7-methyl-4-
[(2E)-3-(3-pyridinyl)-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305804-04-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-(phenylmethyl)-1-(1-
pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305804-26-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(2,5-dihydro-1H-pyrrol-1-yl)-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 305804-29-9 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-iodo-4-(phenylmethyl)-1-(1-
pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305804-30-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-(hexahydro-1H-azepin-1-yl)-7-
methyl-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 305804-56-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 4-[(4-aminophenyl)methyl]-7-bromo-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305804-61-9 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-amino-4-[(2E)-3-phenyl-2-propenyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305804-62-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-amino-1-(hexahydro-1H-azepin-1-yl)-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 305804-65-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-amino-4-[(2E)-3-(3-pyridinyl)-2-propenyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305804-67-5 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-amino-1-(dimethylamino)-4-[(2E)-3-phenyl-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305804-68-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-(methylamino)-4-(phenylmethyl)-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305804-69-7 CAPLUS
CN Benzonitrile, 4-[[7-(methylamino)-5-oxo-1-(1-pyrrolidinyl)[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305804-71-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-(ethylamino)-4-(phenylmethyl)-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305804-72-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-[(1-methylethyl)amino]-4-(phenylmethyl)-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305804-77-7 CAPLUS
CN Benzeneacetic acid, 4-[[7-bromo-5-oxo-1-(1-pyrrolidinyl)[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 305804-78-8 CAPLUS
CN Benzeneacetamide, 4-[[7-bromo-5-oxo-1-(1-pyrrolidinyl)[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 305804-80-2 CAPLUS
CN Benzeneacetamide, 4-[[7-bromo-5-oxo-1-(1-pyrrolidinyl)[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 305804-81-3 CAPLUS
CN Benzeneacetamide, 4-[[7-bromo-5-oxo-1-(1-pyrrolidinyl)[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 305804-84-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-5(4H)-thione, 1-(dimethylamino)-7-methyl-4-[(2E)-3-(3-pyridinyl)-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **305805-19-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(1-aminotriazolo[4,3-a]quinazolin-5-ones and -5-thiones inhibiting phosphodiesterase IV)
RN 305805-19-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-(hexahydro-1H-azepin-1-yl)-4-
(phenylmethyl)- (9CI) (CA INDEX NAME)



IT **305805-06-5P 305805-10-1P 305805-12-3P**
305805-15-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(1-aminotriazolo[4,3-a]quinazolin-5-ones and -5-thiones inhibiting phosphodiesterase IV)
RN 305805-06-5 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-amino-7-bromo-4-
(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 305805-10-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-[[(4-methylphenyl)sulfonyl]oxy]-4-(phenylmethyl)-1-(1-pyrrolidinyl)- (9CI)

(CA
INDEX NAME)



RN 305805-12-3 CAPLUS
CN Benzonitrile, 4-[[7-[[(4-methylphenyl)sulfonyl]oxy]-5-oxo-1-(1-pyrrolidinyl)[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI)
(CA
INDEX NAME)



RN 305805-15-6 CAPLUS
CN Benzeneacetyl chloride, 4-[[7-bromo-5-oxo-1-(1-pyrrolidinyl)[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI)
(CA
INDEX NAME)



IT **305802-96-4P 305804-28-8P 305804-33-5P**
305804-59-5P 305804-60-8P 305804-63-1P
305804-75-5P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(1-aminotriazolo[4,3-a]quinazolin-5-ones and -5-thiones inhibiting phosphodiesterase IV)

RN 305802-96-4 CAPLUS

CN Benzeneacetic acid, 4-[[7-bromo-5-oxo-1-(1-pyrrolidinyl)[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305804-28-8 CAPLUS

CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(methylamino)-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 305804-33-5 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-methyl-4-(phenylmethyl)-1-(4-
thiomorpholinyl)- (9CI) (CA INDEX NAME)



RN 305804-59-5 CAPLUS
CN Acetamide, N-[4,5-dihydro-5-oxo-4-(phenylmethyl)-1-(1-pyrrolidinyl)[1,2,4]triazolo[4,3-a]quinazolin-7-yl]- (9CI) (CA INDEX NAME)



RN 305804-60-8 CAPLUS
CN Acetamide, N-[4,5-dihydro-5-oxo-4-[(2E)-3-phenyl-2-propenyl]-1-(1-pyrrolidinyl)[1,2,4]triazolo[4,3-a]quinazolin-7-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305804-63-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-amino-4-(phenylmethyl)-1-(1-
pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305804-75-5 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carbonitrile, 1-(dimethylamino)-4,5-dihydro-5-oxo-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT **305802-42-0P 305802-44-2P 305802-45-3P**
305802-46-4P 305802-47-5P 305802-48-6P
305802-49-7P 305802-50-0P 305802-52-2P
305802-54-4P 305802-55-5P 305802-56-6P
305802-57-7P 305802-58-8P 305802-59-9P
305802-61-3P 305802-63-5P 305802-64-6P
305802-65-7P 305802-66-8P 305802-67-9P
305802-68-0P 305802-69-1P 305802-70-4P
305802-71-5P 305802-73-7P 305802-76-0P
305802-78-2P 305802-79-3P 305802-85-1P
305802-93-1P 305802-94-2P 305802-95-3P
305802-98-6P 305803-03-6P 305803-04-7P
305803-05-8P 305803-06-9P 305803-07-0P
305803-08-1P 305803-09-2P 305803-10-5P

305803-11-6P 305803-12-7P 305803-13-8P
305803-14-9P 305803-17-2P 305803-22-9P
305803-24-1P 305803-26-3P 305803-27-4P
305803-28-5P 305803-30-9P 305803-35-4P
305803-37-6P 305803-39-8P 305803-40-1P
305803-45-6P 305803-46-7P 305803-47-8P
305803-48-9P 305803-49-0P 305803-50-3P
305803-51-4P 305803-52-5P 305803-53-6P
305803-54-7P 305803-55-8P 305803-56-9P
305803-57-0P 305803-58-1P 305803-59-2P
305803-60-5P 305803-61-6P 305803-62-7P
305803-63-8P 305803-64-9P 305803-65-0P
305803-66-1P 305803-67-2P 305803-68-3P
305803-69-4P 305803-70-7P 305803-71-8P
305803-72-9P 305803-73-0P 305803-74-1P
305803-75-2P 305803-76-3P 305803-77-4P
305803-78-5P 305803-79-6P 305803-81-0P
305803-82-1P 305803-83-2P 305803-84-3P
305803-85-4P 305803-86-5P 305803-87-6P
305803-88-7P 305803-89-8P 305803-90-1P
305803-91-2P 305803-92-3P 305803-93-4P
305803-94-5P 305803-95-6P 305803-96-7P
305803-97-8P 305803-98-9P 305803-99-0P
305804-00-6P 305804-01-7P 305804-02-8P
305804-03-9P 305804-05-1P 305804-06-2P
305804-07-3P 305804-08-4P 305804-09-5P
305804-10-8P 305804-11-9P 305804-12-0P
305804-13-1P 305804-14-2P 305804-15-3P
305804-16-4P 305804-17-5P 305804-18-6P
305804-19-7P 305804-20-0P 305804-21-1P
305804-22-2P 305804-23-3P 305804-24-4P
305804-25-5P 305804-27-7P 305804-31-3P
305804-32-4P 305804-34-6P 305804-35-7P
305804-36-8P 305804-37-9P 305804-38-0P
305804-39-1P 305804-40-4P 305804-41-5P
305804-42-6P 305804-43-7P 305804-44-8P
305804-45-9P 305804-46-0P 305804-47-1P
305804-48-2P 305804-49-3P 305804-50-6P
305804-51-7P 305804-52-8P 305804-53-9P
305804-54-0P 305804-55-1P 305804-57-3P
305804-58-4P 305804-64-2P 305804-66-4P
305804-70-0P 305804-73-3P 305804-74-4P
305804-76-6P 305804-79-9P 305804-82-4P
305804-83-5P 305804-85-7P 305806-28-4P
305819-85-6P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(1-aminotriazolo[4,3-a]quinazolin-5-ones and -5-thiones inhibiting phosphodiesterase IV)

RN 305802-42-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-3-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)



RN 305802-44-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-(3-pyridinylmethyl)-
1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305802-45-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-bromo-3-(3-pyridinylmethyl)-
1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305802-46-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-(hexahydro-1H-azepin-1-yl)-4-
[(2E)-3-phenyl-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305802-47-5 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-4-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 305802-48-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-4-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 305802-49-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-4-[(2-chlorophenyl)methyl]-1-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



RN 305802-50-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-4-[(3-chlorophenyl)methyl]-1-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



RN 305802-52-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 4-[(4-bromophenyl)methyl]-7-chloro-1-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



RN 305802-54-4 CAPLUS

CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-4-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 305802-55-5 CAPLUS
CN Benzonitrile, 4-[[7-chloro-1-(hexahydro-1H-azepin-1-yl)-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305802-56-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-4-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 305802-57-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-4-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 305802-58-8 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-4-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 305802-59-9 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-4-[(3,4-

dichlorophenyl)methyl]-1-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



RN 305802-61-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 305802-63-5 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 305802-64-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-4-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 305802-65-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-4-[2-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 305802-66-8 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-4-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 305802-67-9 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-4-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 305802-68-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-4-[2-(4-methoxyphenyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 305802-69-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-4-[2-(4-chlorophenyl)-
2-oxoethyl]-1-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



RN 305802-70-4 CAPLUS
CN Benzoic acid, 5-[[7-chloro-1-(hexahydro-1H-azepin-1-yl)-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]acetyl]-2-methoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 305802-71-5 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-4-(3-pyridinylmethyl)-
1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305802-73-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-[(4-fluorophenyl)methyl]-1-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



RN 305802-76-0 CAPLUS
RN 305802-78-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-[(2E)-3-(4-chlorophenyl)-2-propenyl]-1-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305802-79-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(hexahydro-1H-azepin-
1-yl)-4-[(2E)-3-(4-methoxyphenyl)-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305802-85-1 CAPLUS
CN Benzonitrile, 3-[[7-bromo-5-oxo-1-(1-pyrrolidinyl)[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305802-93-1 CAPLUS

CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 4-(1,3-benzodioxol-5-ylmethyl)-
7-bromo-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305802-94-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-[(3,5-dimethoxyphenyl)methyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305802-95-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(1-pyrrolidinyl)-4-
[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 305802-98-6 CAPLUS

CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-[(2Z)-3-phenyl-2-propenyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305803-03-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-(1H-imidazol-4-ylmethyl)-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305803-04-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-[(3,5-dimethyl-4-isoxazolyl)methyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305803-05-8 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-(cyclopentylmethyl)-

1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305803-06-9 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-butyl-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305803-07-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(1-pyrrolidinyl)-4-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 305803-08-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-(2-hydroxyethyl)-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305803-09-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-[2-(diethylamino)ethyl]-1-(1-pyrrolidinyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 305803-10-5 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-(2-propynyl)-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305803-11-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-(2-phenoxyethyl)-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305803-12-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-[2-(phenylthio)ethyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305803-13-8 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-4(5H)-acetic acid, 7-bromo-5-oxo-.alpha.-phenyl-1-(1-pyrrolidinyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 305803-14-9 CAPLUS
CN Benzonitrile, 4-[[7-bromo-5-oxo-1-(1-piperidinyl)[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305803-17-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-[(2E)-3-(3-pyridinyl)-2-propenyl]-1-(4-thiomorpholinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305803-22-9 CAPLUS
CN Benzeneacetic acid, 4-[[7-bromo-1-(dimethylamino)-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305803-24-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(dimethylamino)-4-(3-
pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 305803-26-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(dimethylamino)-4-[(2Z)-3-phenyl-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305803-27-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(dimethylamino)-4-[(2E)-3-(4-pyridinyl)-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305803-28-5 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(dimethylamino)-4-(2-
propynyl)- (9CI) (CA INDEX NAME)



RN 305803-30-9 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-4(5H)-acetic acid, 7-bromo-1-(dimethylamino)-5-oxo-.alpha.-phenyl-, methyl ester (9CI) (CA INDEX NAME)



RN 305803-35-4 CAPLUS
CN Benzoic acid, 4-[[7-methyl-5-oxo-1-(1-pyrrolidinyl)[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 305803-37-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-methyl-4-(3-pyridinylmethyl)-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305803-39-8 CAPLUS
CN Benzeneacetic acid, 4-[[7-methyl-5-oxo-1-(4-thiomorpholinyl)[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305803-40-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-methyl-4-[(2E)-3-(3-pyridinyl)-2-propenyl]-1-(4-thiomorpholinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305803-45-6 CAPLUS

CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-(dimethylamino)-7-methyl-4-
[(2E)-3-(4-pyridinyl)-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305803-46-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-(hexahydro-1H-azepin-1-yl)-8-
methyl-4-[(2E)-3-phenyl-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305803-47-8 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carbonitrile, 4-[(4-cyanophenyl)methyl]-1-(dimethylamino)-4,5-dihydro-5-oxo- (9CI) (CA INDEX
NAME)



RN 305803-48-9 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-hydroxy-4-[(2E)-3-phenyl-2-
propenyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305803-49-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 1-(hexahydro-1H-azepin-1-yl)-3-
[(2E)-3-phenyl-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305803-50-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-3-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 305803-51-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 305803-52-5 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-3-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 305803-53-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-chloro-3-[(2-chlorophenyl)methyl]-1-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



RN 305803-54-7 CAPLUS

CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-chloro-3-[(3-chlorophenyl)methyl]-1-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



RN 305803-55-8 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-chloro-3-[(4-chlorophenyl)methyl]-1-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



RN 305803-56-9 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 3-[(4-bromophenyl)methyl]-7-chloro-1-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



RN 305803-57-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-chloro-3-[(4-fluorophenyl)methyl]-1-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



RN 305803-58-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-3-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 305803-59-2 CAPLUS
CN Benzonitrile, 4-[[7-chloro-1-(hexahydro-1H-azepin-1-yl)-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-3(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305803-60-5 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-3-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 305803-61-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-chloro-1-(hexahydro-1H-

azepin-1-yl)-3-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 305803-62-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 305803-63-8 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-chloro-3-[(3,4-dichlorophenyl)methyl]-1-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



RN 305803-64-9 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-chloro-3-[(3,4-dimethoxyphenyl)methyl]-1-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



RN 305803-65-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-3-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 305803-66-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-3-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 305803-67-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 305803-68-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-3-[2-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 305803-69-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-3-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 305803-70-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-3-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 305803-71-8 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-3-[2-(4-methoxyphenyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 305803-72-9 CAPLUS

CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-chloro-3-[2-(4-chlorophenyl)-
2-oxoethyl]-1-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



RN 305803-73-0 CAPLUS
CN Benzoic acid, 5-[[7-chloro-1-(hexahydro-1H-azepin-1-yl)-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-3(5H)-yl]acetyl]-2-methoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 305803-74-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-bromo-3-[(4-chlorophenyl)methyl]-1-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



RN 305803-75-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-bromo-3-[(4-fluorophenyl)methyl]-1-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



RN 305803-76-3 CAPLUS
CN Benzonitrile, 4-[[7-bromo-1-(hexahydro-1H-azepin-1-yl)-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-3(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305803-77-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-bromo-3-[(3,4-dimethoxyphenyl)methyl]-1-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



RN 305803-78-5 CAPLUS
CN Benzeneacetic acid, 4-[[7-bromo-1-(hexahydro-1H-azepin-1-yl)-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-3(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305803-79-6 CAPLUS

CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-bromo-1-(hexahydro-1H-azepin-
1-yl)-3-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 305803-81-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-bromo-1-(hexahydro-1H-azepin-
1-yl)-3-[(2E)-3-phenyl-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305803-82-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-bromo-1-(hexahydro-1H-azepin-
1-yl)-3-[(2Z)-3-phenyl-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305803-83-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-bromo-3-[(4-chlorophenyl)methyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305803-84-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-bromo-3-[(4-fluorophenyl)methyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305803-85-4 CAPLUS
CN Benzonitrile, 4-[[7-bromo-5-oxo-1-(1-pyrrolidinyl)[1,2,4]triazolo[4,3-a]quinazolin-3(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305803-86-5 CAPLUS
CN Benzoic acid, 4-[[7-bromo-5-oxo-1-(1-pyrrolidinyl)[1,2,4]triazolo[4,3-a]quinazolin-3(5H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 305803-87-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-bromo-3-[(4-methoxyphenyl)methyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305803-88-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 3-[[4-(acetyloxy)phenyl]methyl]-7-bromo-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305803-89-8 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-bromo-3-[(4-hydroxyphenyl)methyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305803-90-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 3-(1,3-benzodioxol-5-ylmethyl)-
7-bromo-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305803-91-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-bromo-3-[(3,5-dimethoxyphenyl)methyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305803-92-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-bromo-1-(1-pyrrolidinyl)-3-
[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 305803-93-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-bromo-3-butyl-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305803-94-5 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-3(5H)-acetic acid, 7-bromo-5-oxo-.alpha.-
phenyl-1-(1-pyrrolidinyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 305803-95-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-bromo-1-(dimethylamino)-3-[(2E)-3-phenyl-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305803-96-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-3(5H)-acetic acid, 7-bromo-1-(dimethylamino)-5-oxo-.alpha.-phenyl-, methyl ester (9CI) (CA INDEX NAME)



RN 305803-97-8 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 1-(hexahydro-1H-azepin-1-yl)-7-methyl-3-[(2E)-3-phenyl-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305803-98-9 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-methyl-3-[(2E)-3-phenyl-2-propenyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305803-99-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 1-(hexahydro-1H-azepin-1-yl)-
3,8-dimethyl- (9CI) (CA INDEX NAME)



RN 305804-00-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 8-methyl-3-[(2E)-3-phenyl-2-propenyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305804-01-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-hydroxy-3-[(2E)-3-phenyl-2-propenyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305804-02-8 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-(hexahydro-1H-azepin-1-yl)-3-
[(2E)-3-phenyl-2-propenyl]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305804-03-9 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(hexahydro-1H-azepin-
1-yl)-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 305804-05-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(butylmethylamino)-4-
(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 305804-06-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 4-(phenylmethyl)-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305804-07-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-1-(dibutylamino)-4-methyl- (9CI) (CA INDEX NAME)



RN 305804-08-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-4-methyl-1-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 305804-09-5 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-4-methyl-1-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 305804-10-8 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-4-methyl-1-(1,8,8-trimethyl-3-azabicyclo[3.2.1]oct-3-yl)- (9CI) (CA INDEX NAME)



RN 305804-11-9 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 305804-12-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 305804-13-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-4-(phenylmethyl)-1-(1-
pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305804-14-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-4-(phenylmethyl)-1-(1-
piperidinyl)- (9CI) (CA INDEX NAME)



RN 305804-15-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 8-chloro-1-(hexahydro-1H-azepin-1-yl)-4-methyl- (9CI) (CA INDEX NAME)



RN 305804-16-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 8-chloro-1-(hexahydro-1H-azepin-1-yl)-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 305804-17-5 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(hexahydro-1H-azepin-
1-yl)-4-methyl- (9CI) (CA INDEX NAME)



RN 305804-18-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-(phenylmethyl)-1-(1-
piperidinyl)- (9CI) (CA INDEX NAME)



RN 305804-19-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(dimethylamino)-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 305804-20-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(4-morpholinyl)-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 305804-21-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-(phenylmethyl)-1-(4-
thiomorpholinyl)- (9CI) (CA INDEX NAME)



RN 305804-22-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(4-methyl-1-piperazinyl)-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 305804-23-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-(phenylmethyl)-1-(4-phenyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 305804-24-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-(phenylmethyl)-1-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 305804-25-5 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(3,6-dihydro-

1(2H)-
pyridinyl)-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 305804-27-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(3-hydroxy-1-pyrrolidinyl)-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 305804-31-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-methyl-4-(phenylmethyl)-1-(1-
pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305804-32-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-(dimethylamino)-7-methyl-4-
(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 305804-34-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-(hexahydro-1H-azepin-1-yl)-8-
methyl-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 305804-35-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-(hexahydro-1H-azepin-1-yl)-7-
methoxy-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 305804-36-8 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-methoxy-4-(phenylmethyl)-1-
(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305804-37-9 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carbonitrile, 4,5-dihydro-5-oxo-4-(phenylmethyl)-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305804-38-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-(hexahydro-1H-azepin-1-yl)-7-
nitro-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 305804-39-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-(hexahydro-1H-azepin-1-yl)-4-
methyl- (9CI) (CA INDEX NAME)



RN 305804-40-4 CAPLUS
RN 305804-41-5 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 6-chloro-1-(hexahydro-1H-azepin-1-yl)-4-methyl- (9CI) (CA INDEX NAME)



RN 305804-42-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-1-(hexahydro-1H-azepin-1-yl)-4-methyl- (9CI) (CA INDEX NAME)



RN 305804-43-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-4-ethyl-1-(hexahydro-
1H-azepin-1-yl)- (9CI) (CA INDEX NAME)



RN 305804-44-8 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-4-methyl-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305804-45-9 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-4-methyl-1-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 305804-46-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-1-(3,4-dihydro-1(2H)-quinolinyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 305804-47-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-1-(3,4-dihydro-2(1H)-
isoquinolinyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 305804-48-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-4-methyl-1-[4-(phenylmethyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 305804-49-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-4-methyl-1-(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)- (9CI) (CA INDEX NAME)



RN 305804-50-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-fluoro-1-(hexahydro-1H-azepin-1-yl)-4-methyl- (9CI) (CA INDEX NAME)



RN 305804-51-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-(hexahydro-1H-azepin-1-yl)-7-
iodo-4-methyl- (9CI) (CA INDEX NAME)



RN 305804-52-8 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-(hexahydro-1H-azepin-1-yl)-7-
methoxy-4-methyl- (9CI) (CA INDEX NAME)



RN 305804-53-9 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-1-(ethylmethylamino)-4-
(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 305804-54-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-(diethylamino)-7-methyl-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 305804-55-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-bromo-4-(phenylmethyl)-1-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 305804-57-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-hydroxy-4-(phenylmethyl)-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305804-58-4 CAPLUS
CN Benzonitrile, 4-[[7-hydroxy-5-oxo-1-(1-pyrrolidinyl)[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305804-64-2 CAPLUS
CN Benzonitrile, 4-[[7-amino-5-oxo-1-(1-pyrrolidinyl)[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305804-66-4 CAPLUS
CN Benzonitrile, 4-[[7-amino-1-(dimethylamino)-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305804-70-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 8-(methylamino)-4-(phenylmethyl)-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305804-73-3 CAPLUS
CN Methanesulfonamide, N-[4,5-dihydro-5-oxo-4-(phenylmethyl)-1-(1-pyrrolidinyl)[1,2,4]triazolo[4,3-a]quinazolin-7-yl]- (9CI) (CA INDEX NAME)



RN 305804-74-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-(dimethylamino)-4-(phenylmethyl)-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305804-76-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carboxylic acid, 4,5-dihydro-5-oxo-4-
(phenylmethyl)-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305804-79-9 CAPLUS
CN Benzeneacetamide, 4-[[7-bromo-5-oxo-1-(1-pyrrolidinyl)[1,2,4]triazolo[4,3-
a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305804-82-4 CAPLUS
CN Benzonitrile, 4-[[1-(dimethylamino)-7-methyl-5-thioxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305804-83-5 CAPLUS
CN Benzonitrile, 4-[[7-bromo-1-(dimethylamino)-5-thioxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 305804-85-7 CAPLUS
CN Methanesulfonamide, N-[4,5-dihydro-5-oxo-4-(phenylmethyl)-1-(1-pyrrolidinyl)[1,2,4]triazolo[4,3-a]quinazolin-7-yl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 305806-28-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-chloro-1-(hexahydro-1(2H)-azocinyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 305819-85-6 CAPLUS

CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-bromo-3-(1H-imidazol-4-ylmethyl)-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 1999:571561 CAPLUS
DN 131:310617
TI Novel triazolo[4,3-a]quinazolinone and bis-triazolo[4,3-a:4,3'-c]quinazolines: synthesis and antitoxoplasmosis effect
AU El-Tombary, Alaa A.; Ismail, Khadiga A.; Aboulwafa, Omaima M.; Omar, A.-Mohsen M. E.; El-Azzouni, Mervat Z.; El-Mansoury, Salwa T.
CS Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Alexandria, Alexandria, 21215, Egypt
SO Farmaco (1999), 54(7), 486-495
CODEN: FRMCE8; ISSN: 0014-827X
PB Elsevier Science S.A.
DT Journal
LA English
OS CASREACT 131:310617
AB Several quinazoline derivs. contg. substituted thiosemicarbazido and S-methylisothiosemicarbazido groups at the 2-position and at both the 2- and 4-positions were synthesized. Treatment of the S-methylthiosemicarbazides with morpholine or diethylamine did not give the corresponding guanidines. Instead, they underwent cyclodesulfurization into the condensed ring systems, [1,2,4]triazolo[4,3-a]quinazolinones and bis-[1,2,4]triazolo[4,3-a:4',3'-c]quinazolines. Evaluation of the products for antitoxoplasmosis effect by studying the ultrastructure morphol. of the organisms using SEM indicated their efficacy in causing structural deformity of Toxoplasma gondii. Such a deformity plays an important role in obstructing the entry of the organisms into host cells.
IT **247257-98-3P 247258-00-0P 247258-01-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reactant for prepn. of triazolo[4,3-a]quinazolinones)
RN 247257-98-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 4-methyl-1-(phenylamino)- (9CI) (CA INDEX NAME)



RN 247258-00-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 4-methyl-1-[(4-methylphenyl)amino]- (9CI) (CA INDEX NAME)



RN 247258-01-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-[(4-methoxyphenyl)amino]-4-methyl- (9CI) (CA INDEX NAME)



IT **247257-99-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL(Biological study); PREP (Preparation); RACT (Reactant or reagent) (prepn. and reactant for prepn. of triazolo[4,3-a]quinazolinones and antitoxoplasmosis effect)
RN 247257-99-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-[(4-chlorophenyl)amino]-4-methyl- (9CI) (CA INDEX NAME)



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 1983:470757 CAPLUS
DN 99:70757
TI 1,4,7,9-Differently substituted 4,5-dihydro-s-triazolo[4,3-a]quinazolin-5-ones
IN Kottke, Karl; Kuehmstedt, Hans; Hagen, Volker; Renner, Helga; Schnitzler, Stephan
PA Akademie der Wissenschaften der DDR, Ger. Dem. Rep.
SO Ger. (East), 27 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DD 158549	Z	19830119	DD 1981-229905	19810513
PRAI DD 1981-229905		19810513		

GI



I

AB Triazoloquinazolinones I [R, R1 = H, alkyl, halo, alkoxy, alkylthio; R2 = H, OH, SH, alkoxy, alkylthio, amino, (un)substituted alkyl, aryl, etc.; R3 = H, alkyl, (un)substituted aryl] were prepd. Thus, 3-(3-methylphenyl-2-hydrazino-4(3H)quinazolinolinone was cyclocondensed with HCO2H to give 92% I (R = R1 = H, R2 = OH, R3 = 3-MeC6H4) (II). II gave 30% inhibition of passive cutaneous anaphylaxis in rats.

IT **85772-75-4P 85772-87-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)(prepn. of)

RN 85772-75-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-amino-7-chloro-4-phenyl- (9CI) (CA INDEX NAME)



RN 85772-87-8 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-amino-7-bromo-4-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 1983:198151 CAPLUS
DN 98:198151
TI Synthesis of compounds with aminoguanidine structure. Part 8. 1,4,7,9-Substituted 4,5-dihydro-s-triazolo[4,3-a]quinazolin-5-ones and 4,5-dihydrotetrazolo[1,5-a]quinazolin-5-ones
AU Kottke, K.; Kuehmstedt, H.; Knoke, D.
CS Sekt. Pharm., Ernst-Moritz-Arndt-Univ., Greifswald, Ger. Dem. Rep.
SO Pharmazie (1983), 38(1), 25-8
CODEN: PHARAT; ISSN: 0031-7144
DT Journal
LA German
OS CASREACT 98:198151
GI



I



II

AB Triazoloquinazolinones I [R1 = Me, MeO, BuO, Cl, Br, 4-F, isoamyloxy, Me2; R2 = H, Cl, Br; R3 = H, Br; X = CH, CMe, COH, CSR4 (R4 = H, Et, Pr), CNH2, CCH2Cl, CPh, CCH2CO2Et, etc.] and tetrazoloquinazolinones I [R1 = BuO, Me2, H; R2 = H, Cl, Br; R3 = H, Cl; X = N] were prepd. by reaction of hydrazinoquinazolinones II with carboxylic acids, alkanoyl chlorides, COCl2, CSCl2, BrCN, and dialkyl alkanedicarboxylates.
IT **85772-75-4P 85772-87-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 85772-75-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-amino-7-chloro-4-phenyl- (9CI) (CA INDEX NAME)



RN 85772-87-8 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-amino-7-bromo-4-phenyl- (9CI) (CA INDEX NAME)



L9 ANSWER 1 OF 8 BEILSTEIN COPYRIGHT 2003 BEILSTEIN CDS MDL

Beilstein Records (BRN):	8709485
Chemical Name (CN):	4-methyl-1-piperidino-4,5-dihydro<1,2,4>triazolo<4,3-a>quinazolin-5-one
Autonom Name (AUN):	4-methyl-1-piperidin-1-yl-4H-<1,2,4>triazolo<4,3-a>quinazolin-5-one
Molec. Formula (MF):	C15 H17 N5 O
Molecular Weight (MW):	283.33
Lawson Number (LN):	30728, 24081, 2817
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	7376948
Tautomer ID (TAUTID):	8178608
Entry Date (DED):	2001/04/26
Update Date (DUPD):	2001/04/26



Reference(s):

1. Fathalla, W.; Cajan, M.; Pazdera, P., Molecules, CODEN: MOLEFW, 5(12), <2000>, 1210 - 1223; BABS-6263110

L9 ANSWER 2 OF 8 BEILSTEIN COPYRIGHT 2003 BEILSTEIN CDS MDL

Beilstein Records (BRN):	8708575
Chemical Name (CN):	4-methyl-1-(4-methylpiperazino)-4,5-dihydro<1,2,4>triazolo<4,3-a>quinazolin-5-one
Autonom Name (AUN):	4-methyl-1-(4-methyl-piperazin-1-yl)-4H-<1,2,4>triazolo<4,3-a>quinazolin-5-one
Molec. Formula (MF):	C15 H18 N6 O
Molecular Weight (MW):	298.35
Lawson Number (LN):	30728, 28000, 2817
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	7376059
Tautomer ID (TAUTID):	8178312
Entry Date (DED):	2001/04/26
Update Date (DUPD):	2001/04/26



Reference(s):

1. Fathalla, W.; Cajan, M.; Pazdera, P., Molecules, CODEN: MOLEFW, 5(12), <2000>, 1210 - 1223; BABS-6263110

L9 ANSWER 3 OF 8 BEILSTEIN COPYRIGHT 2003 BEILSTEIN CDS MDL

Beilstein Records (BRN):	8705504
Chemical Name (CN):	4-methyl-1-morpholino-4,5-dihydro<1,2,4>triazolo<4,3-a>quinazolin-5-one
Autonom Name (AUN):	4-methyl-1-morpholin-4-yl-4H-<1,2,4>triazolo<4,3-a>quinazolin-5-one
Molec. Formula (MF):	C14 H15 N5 O2
Molecular Weight (MW):	285.30
Lawson Number (LN):	30824, 30728, 2817
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	7373510
Tautomer ID (TAUTID):	8176721
Entry Date (DED):	2001/04/26
Update Date (DUPD):	2001/04/26



Reference(s):

1. Fathalla, W.; Cajan, M.; Pazdera, P., Molecules, CODEN: MOLEFW, 5(12), <2000>, 1210 - 1223; BABS-6263110

L9 ANSWER 4 OF 8 BEILSTEIN COPYRIGHT 2003 BEILSTEIN CDS MDL

Beilstein Records (BRN):	8702100
Chemical Name (CN):	4-methyl-1-pyrrolidino-4,5-dihydro<1,2,4>triazolo<4,3-a>quinazolin-5-one
Autonom Name (AUN):	4-methyl-1-pyrrolidin-1-yl-4H-<1,2,4>triazolo<4,3-a>quinazolin-5-one
Molec. Formula (MF):	C14 H15 N5 O
Molecular Weight (MW):	269.31
Lawson Number (LN):	30728, 24077, 2817
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	7370619
Tautomer ID (TAUTID):	8175183
Entry Date (DED):	2001/04/26
Update Date (DUPD):	2001/04/26



Reference(s):

1. Fathalla, W.; Cajan, M.; Pazdera, P., Molecules, CODEN: MOLEFW, 5(12), <2000>, 1210 - 1223; BABS-6263110

L9 ANSWER 5 OF 8 BEILSTEIN COPYRIGHT 2003 BEILSTEIN CDS MDL

Beilstein Records (BRN):	8500358
Chemical Name (CN):	1-(4-chloro-phenylamino)-4-methyl-4H-<1,2,4>triazolo<4,3-a>quinazolin-5-one
Autonom Name (AUN):	1-(4-chloro-phenylamino)-4-methyl-4H-<1,2,4>triazolo<4,3-a>quinazolin-5-one
Molec. Formula (MF):	C16 H12 Cl N5 O
Molecular Weight (MW):	325.76
Lawson Number (LN):	30728, 14132, 2817
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	7207419
Tautomer ID (TAUTID):	8014872
Entry Date (DED):	2000/07/18
Update Date (DUPD):	2000/07/18



Reference(s):

1. El-Tombary, Alaa A.; Ismail, Khadiga A.; Aboulwafa, Omaima M.; Omar, A.-Mohsen M. E.; El-Azzouni, Mervat Z.; El-Mansoury, Salwa T., Farmaco, CODEN: FRMCE8, 54(7), <1999>, 486 - 496; BABS-6229194

L9 ANSWER 6 OF 8 BEILSTEIN COPYRIGHT 2003 BEILSTEIN CDS MDL

Beilstein Records (BRN):	8499144
Chemical Name (CN):	1-(4-methoxy-phenylamino)-4-methyl-4H-<1,2,4>triazolo<4,3-a>quinazolin-5-one
Autonom Name (AUN):	1-(4-methoxy-phenylamino)-4-methyl-4H-<1,2,4>triazolo<4,3-a>quinazolin-5-one
Molec. Formula (MF):	C17 H15 N5 O2
Molecular Weight (MW):	321.34
Lawson Number (LN):	30728, 14892, 2817, 289
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	7206498
Tautomer ID (TAUTID):	8015148
Entry Date (DED):	2000/07/18
Update Date (DUPD):	2000/07/18



Reference(s):

1. El-Tombary, Alaa A.; Ismail, Khadiga A.; Aboulwafa, Omaima M.; Omar, A.-Mohsen M. E.; El-Azzouni, Mervat Z.; El-Mansoury, Salwa T., Farmaco, CODEN: FRMCE8, 54(7), <1999>, 486 - 496; BABS-6229194

L9 ANSWER 7 OF 8 BEILSTEIN COPYRIGHT 2003 BEILSTEIN CDS MDL

Beilstein Records (BRN):	8497428
Chemical Name (CN):	4-methyl-1-p-tolylamino-4H-<1,2,4>triazolo<4,3-a>quinazolin-5-one
Autonom Name (AUN):	4-methyl-1-p-tolylamino-4H-<1,2,4>triazolo<4,3-a>quinazolin-5-one
Molec. Formula (MF):	C17 H15 N5 O
Molecular Weight (MW):	305.34
Lawson Number (LN):	30728, 14141, 2817
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	7204932
Tautomer ID (TAUTID):	8016130
Entry Date (DED):	2000/07/18
Update Date (DUPD):	2000/07/18



Reference(s):

1. El-Tombary, Alaa A.; Ismail, Khadiga A.; Aboulwafa, Omaima M.; Omar, A.-Mohsen M. E.; El-Azzouni, Mervat Z.; El-Mansoury, Salwa T., Farmaco, CODEN: FRMCE8, 54(7), <1999>, 486 - 496; BABS-6229194

L9 ANSWER 8 OF 8 BEILSTEIN COPYRIGHT 2003 BEILSTEIN CDS MDL

Beilstein Records (BRN):	8494350
Chemical Name (CN):	4-methyl-1-phenylamino-4H-<1,2,4>triazolo<4,3-a>quinazolin-5-one
Autonom Name (AUN):	4-methyl-1-phenylamino-4H-<1,2,4>triazolo<4,3-a>quinazolin-5-one
Molec. Formula (MF):	C16 H13 N5 O
Molecular Weight (MW):	291.31
Lawson Number (LN):	30728, 14131, 2817
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	7202217
Tautomer ID (TAUTID):	8012996
Entry Date (DED):	2000/07/18
Update Date (DUPD):	2000/07/18



Reference(s):

1. El-Tombary, Alaa A.; Ismail, Khadiga A.; Aboulwafa, Omaima M.; Omar, A.-Mohsen M. E.; El-Azzouni, Mervat Z.; El-Mansoury, Salwa T., Farmaco, CODEN: FRMCE8, 54(7), <1999>, 486 - 496; BABS-6229194

L15 ANSWER 1 OF 1 MARPAT COPYRIGHT 2003 ACS
AN 137:185503 MARPAT
TI Triazolopyrimidinones as MMP inhibitors
IN Andrianjara, Charles; Jacobelli, Henry; Gaudilliere, Bernard; Breuzard, Francine
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002064595	A1	20020822	WO 2002-EP1961	20020211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002151558	A1	20021017	US 2002-75654	20020214

PRAI US 2001-268757P 20010214
GI



I

AB Title compds. I [W, X = N, (un)substituted CH; Y = O, S, NH, N-alkyl; Z = O, S, (un)substituted NH, CH2; Z1 = (un)substituted CH2; n = 0-8; R = (un)substituted 5-6-membered ring, bicyclic ring system, optionally contg. 1-4 N, O, and/or S atoms; R1 = H, (un)substituted alkyl, alkenyl, alkynyl] and their N-oxides were prepd.for use as specific inhibitors of type-13 matrix metalloprotease. Thus, 4-benzyl-7-bromo-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one was converted to the nitrile, hydrolyzed to the acid and esterified to give the benzyl ester which had an IC50 for inhibition of MMP-13 of 0.0034 .mu.M.

MSTR 1



.G1 = 223



G2 = Hy<EC (1) Q (0-) N (0-) O (0-) S (0) OTHERQ (-8) C, AR (0), BD (ALL) SE> (SO G6)
G4 = N
G31 = Cb<EC (5-10) C, RC (1-2), RS (0-) E5 (0-) E6 (0) OTHER> (SO (1-7) G37)
MPL: claim 1
NTE: substitution is restricted
NTE: additional interruptions in G14 and G32 also claimed
NTE: and pharmaceutically acceptable salts and N-oxides
STE: and isomers and racemic forms

MSTR 2



G1 = 223



G2 = Hy<EC (1) Q (0-) N (0-) O (0-) S (0) OTHERQ (-8) C, AR (0), BD (ALL) SE> (SO G6)
G4 = N
G31 = Cb<EC (5-10) C, RC (1-2), RS (0-) E5 (0-) E6 (0) OTHER> (SO (1-7) G37)
MPL: claim 19
NTE: substitution is restricted
NTE: additional interruptions in G32 also claimed
NTE: also incorporates claims 22 and 27

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d l1; d l3; d his; log y
L1 HAS NO ANSWERS
L1                STR
```



G1 O,S
G2 Ph,Ak

Structure attributes must be viewed using STN Express query preparation.

L3 HAS NO ANSWERS
L3 STR



G1 O,S
G2 Ph,Ak

Structure attributes must be viewed using STN Express query preparation.

```
     (FILE 'HOME' ENTERED AT 11:57:49 ON 12 FEB 2003)
     FILE 'REGISTRY' ENTERED AT 11:57:56 ON 12 FEB 2003
L1                STRUCTURE UPLOADED
L2              7 S L1
     FILE 'STNGUIDE' ENTERED AT 11:58:22 ON 12 FEB 2003
     FILE 'REGISTRY' ENTERED AT 11:59:13 ON 12 FEB 2003
L3                STRUCTURE UPLOADED
L4              3 S L3
L5            259 S L1 OR L3 FUL
     FILE 'CAPLUS' ENTERED AT 11:59:54 ON 12 FEB 2003
L6              5 S L5
     FILE 'BEILSTEIN' ENTERED AT 12:00:48 ON 12 FEB 2003
L7              2 S L1 OR L3
L8             10 S L1 OR L3 FUL
L9              8 S L8 NOT L6
     FILE 'MARPAT' ENTERED AT 12:01:46 ON 12 FEB 2003
L10             0 S L1
```

L11	2	S L1 FUL
L12	0	S L3
L13	1	S L3 FUL
L14	2	S L11 OR L13
L15	1	S L14 NOT L6

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	213.33	820.10

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.62	-3.88

STN INTERNATIONAL LOGOFF AT 12:03:04 ON 12 FEB 2003

INTERMEDIATES

L14 ANSWER 1 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 2002:637681 CAPLUS
DN 137:185503
TI Triazolopyrimidinones as MMP inhibitors
IN Andrianjara, Charles; Jacobelli, Henry; Gaudilliere, Bernard; Breuzard, Francine
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002064595	A1	20020822	WO 2002-EP1961	20020211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002151558	A1	20021017	US 2002-75654	20020214
PRAI US 2001-268757P	P	20010214		

OS MARPAT 137:185503
GI



I

AB Title compds. I [W, X = N, (un)substituted CH; Y = O, S, NH, N-alkyl; Z = O, S, (un)substituted NH, CH2; Z1 = (un)substituted CH2; n = 0-8; R = (un)substituted 5-6-membered ring, bicyclic ring system, optionally contg. 1-4 N, O, and/or S atoms; R1 = H, (un)substituted alkyl, alkenyl, alkynyl] and their N-oxides were prepd.for use as specific inhibitors of type-13 matrix metalloprotease. Thus, 4-benzyl-7-bromo-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one was converted to the nitrile, hydrolyzed to the acid and esterified to give the benzyl ester which had an IC50 for inhibition of MMP-13 of 0.0034 .mu.M.

IT **35977-17-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of triazolopyrimidinones as MMP inhibitors)

RN 35977-17-4 CAPLUS
CN 4(1H)-Quinazolinone, 6-bromo-2,3-dihydro-3-(phenylmethyl)-2-thioxo-

(9CI)
(CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 2002:637660 CAPLUS
DN 137:185501
TI Preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease
IN Andrianjara, Charles; Chantel-Barvian, Nicole; Gaudilliere, Bernard; Jacobelli, Henri; Ortwine, Daniel Fred; Patt, William Chester; Pham, Ly; Kostlan, Catherine Rose; Wilson, Michael William
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 264 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002064572	A1	20020822	WO 2002-EP1979	20020211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002193377	A1	20021219	US 2002-75954	20020213

PRAI US 2001-268661P P 20010214
OS MARPAT 137:185501
GI



I



II

AB Title compds. I [R1 = H, amino, alkyl, alkenyl, alkynyl, alkylamino, aryl, heterocycle, etc.; W = O, S, =N-R'; R' = alkyl, OH, CN; X1-3 = N, C-R6; R6 = H, alkyl, amino, alkylamino, etc.; Y = O, S, NH, N-alkyl; Z = O, S, NR7;

R7 = H, alkyl, aryl, aryl, heteroaryl, etc.; n = 1-8; Z1 = alkyl; A = (non)arom., 5- or 6-membered monocycle comprising from 0 to 4 heteroatoms selected from N, O, S, etc.; m = 0-7; R2 = alkyl, halo, CN, NO2, SCF3, CF3, OCF3, etc.; R3 = H, alkyl, alkenyl, alkynyl, etc.] were prepd. Over 200 synthetic examples were provided. For instance, di-Me 4-aminoisophthalate was reacted with benzylisocyanate and heated to 95-100.degree. overnight to give Me 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylate which was sapond. (dioxaneaq, LiOH, reflux) to give the carboxylic acid. This intermediate was coupled with benzylamine to afford II. Selected examples of I had IC50 = 2.25 - 0.001 .mu.M for MMP13 and IC50 > 100 .mu.M for MMP1, MMP2, MMP3, MMP7, MMP9, MMP12 and MMP14; II had IC50 = 0.193 .mu.M for MMP13. Compds. I are useful for the treatment of osteoarthritis and rheumatoid arthritis.

IT **449208-70-2P**, 3-Benzyl-4-oxo-2-thioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MMP13 inhibitor; prepn. of quinazolines as specific inhibitors of type-13 matrix metalloprotease)

RN 449208-70-2 CAPLUS

CN 6-Quinazolinecarboxamide, N-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro-4-oxo-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 2002:637472 CAPLUS
DN 137:201321
TI Preparation of substituted isophthalic acid derivatives, multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors
IN Andrianjara, Charles; Ortwine, Daniel Fred; Pavlovsky, Alexander Gregory;
Roark, William Howard
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002064080	A2	20020822	WO 2002-IB447	20020213
WO 2002064080	A3	20021212		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-268821P P 20010214
GI



I



II



III

AB Title compds., I [R1 and R2 together may form a substituted arom. ring or a heterocyclic ring; or R2 and R3 together may form substituted heterocycle; or R1, R3, or R4 = alkyl, arylalkyl, etc.; X = C, S; Y = O, N with provision when Y = N it forms a 5-membered heterocycle with R3] and

II [R5, R6 = arylalkylamine, heterocyclylalkoxy, etc.; R7 = H, MeO, NO2, etc.], are prepd. and disclosed as matrix metalloproteinase (MMP) inhibitors. Thus, III was prepd. in five steps via cyclocondensation of diethylmalonate and benzylurea with subsequent chlorination, substitution with hydrosulfide hydrate to form an in situ intermediate that was reacted with bromoacetaldehyde dimethylacetal, followed by acid catalyzed cyclization and substitution with benzylchloroformate. III was demonstrated to inhibit MMP13 with an IC50 value (in .mu.M) of 0.0230. I and II bind allosterically to the catalytic domain of MMP-13 and comprise a hydrophobic group, first and second hydrogen bond acceptors and at least one, and preferably both, of a third hydrogen bond acceptor and a second hydrophobic group. Cartesian coordinates for centroids of the above features are defined in the specification. When the ligand binds to MMP-13, the first, second and third (when present) hydrogen bond acceptors bond resp. with Thr245, Thr247 and Met 253, the first hydrophobic group locates within the S1' channel of MMP-13 and the second hydrophobic group (when present) is relatively open to solvent. The compds. specifically inhibit the matrix metalloproteinase-13 enzyme and thus are useful for treating diseases resulting from tissue breakdown, such as heart disease, multiple sclerosis, arthritis, atherosclerosis, and osteoporosis.

IT **449208-70-2P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)

RN 449208-70-2 CAPLUS

CN 6-Quinazolinecarboxamide, N-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro-4-oxo-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



L14 ANSWER 4 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 2002:216051 CAPLUS
DN 136:241664
TI Pharmaceutical composition for preventing or treating a disease associated
with an excess of IL-12 production
IN Moulon, Corinne; Heysteck, Heleen
PA Warner-Lambert Company, USA
SO Eur. Pat. Appl., 29 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1188438	A1	20020320	EP 2000-402560	20000915
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	EP 1199074	A1	20020424	EP 2001-402325	20010910
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NO 2001004414	A	20020318	NO 2001-4414	20010911
	CN 1348763	A	20020515	CN 2001-138457	20010912
	BR 2001004005	A	20020709	BR 2001-4005	20010912
	JP 2002316948	A2	20021031	JP 2001-277234	20010912
	WO 2002022112	A2	20020321	WO 2001-EP10590	20010913
	W: CO				
	US 2002119967	A1	20020829	US 2001-953822	20010915
PRAI	EP 2000-402560	A	20000915		

AB The invention is directed to the use of a PDE4 inhibitor for manufg. a medicament for preventing and/ or treating a disease assocd. with an excess in IL-12 prodn. as well as to a method for treating such disorders through the use of at least one PDE4 inhibitor. It is also related to a pharmaceutical compn. for preventing and/or treating a disease assocd. with an excess in IL-12 prodn. comprising an effective amt. of at least one PDE4 inhibitor. Diseases assocd. with an excess in IL-12 prodn. encompass autoimmune disorders like inflammation of the bronchi/pathologies affecting the bronchus (bronchorestriction), multiple organ failure, osteoarthritis, septic shock (septicemia), inflammatory complaints or disorders, etc.
IT **404578-73-0D**, derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compn. for preventing or treating a disease assocd. with excess of IL-12 prodn. such as inflammatory disease using phosphodiesterase IV inhibitors)
RN 404578-73-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 1-amino- (9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 5 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 2002:68708 CAPLUS
DN 137:294921
TI Substituted quinazolines, 1. Synthesis and antitumor activity of certain substituted 2-mercapto-4(3H)-quinazolinone analogs
AU Abdel Hamid, S. G.; El-Obeid, H. A.; Al-Rashood, K. A.; Khalil, A. A.; El-Subbagh, H. I.
CS Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia
SO Scientia Pharmaceutica (2001), 69(4), 351-366
CODEN: SCPHA4; ISSN: 0036-8709
PB Oesterreichische Apotheker-Verlagsgesellschaft
DT Journal
LA English
GI



I



II

AB A new series of 4(3H)-quinazolinone analogs bearing 6-iodo and 2-thioether functions, e.g., I, were synthesized and screened for their in vitro antitumor activity. Eight compds. were identified as active anticancer agents. I and quinazolinone II proved to be the most active compds. in this study. They showed MG-MID GI50, TGI, LC50 values of 3.9, 25.2, 82.3 and 2.7, 12.3, 38.7 .mu.M, resp. The detailed synthesis and biol. screening data are reported.
IT **19857-32-0**
RL: PAC (Pharmacological activity); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
(prepn. and antitumor activity of mercaptoquinazolinones via derivation of thiol moiety in mercaptobenzyliodoquinazolinone)
RN 19857-32-0 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-6-iodo-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 2001:501539 CAPLUS
DN 135:272932
TI Synthesis and anticonvulsant activity of some new 4-Oxo-3H-quinazoline analogs
AU Abdel Hamid, Sami G.; El-Obeid, Humeida A.; Al-Majed, Abdelrahman A.; El-Kashef, Hassan A.; El-Subbagh, Hussein I.
CS Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia
SO Medicinal Chemistry Research (2001), 10(6), 378-389
CODEN: MCREEB; ISSN: 1054-2523
PB Birkhaeuser Boston
DT Journal
LA English
OS CASREACT 135:272932
GI



I

AB A new series of 3-benzyl-4-oxo-6-iodo-3H-quinazoline derivs. was synthesized and evaluated for their anticonvulsant activity adopting various screening models. Quinazoline I (R = CH2CO2H) (ED50 73.1 mg/kg) showed a 100% protection against PTZ-induced clonic convulsions with a wide safety margin compared to valproate (ED50 102 mg/kg). Also, compds.
I (R = 2-O2NC6H4, CH2CONHR1, CH2CONHCH2CH2OH, CH2CONHR2, R1 = phthalimido,
R2 = 3,4-dichloromaleimido) showed 83.3% protection. Meanwhile, compds. I
(R = CH2CO2H, 2-O2NC6H4, CH2CONHR1, R1 = phthalimido) proved to be GABA-mimetic agents.
IT **19857-32-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. and anticonvulsant activity of oxoquinazoline analogs)
RN 19857-32-0 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-6-iodo-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 7 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 2001:114660 CAPLUS
DN 134:178565
TI Preparation of mercaptoalkylquinazolinediones and related compounds as inhibitors of matrix metalloproteinase.
IN Leistner, Siegfried; Wippich, Petra; Hermann, Konrad
PA Ibfb G.m.b.H. Privates Institut fuer Biomedizinische Forschung und Beratung, Germany
SO Ger., 26 pp.
CODEN: GWXXAW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19940494	C1	20010215	DE 1999-19940494	19990826
	WO 2001014344	A2	20010301	WO 2000-EP8126	20000821
	WO 2001014344	A3	20010607		
	W: US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1150964	A2	20011107	EP 2000-964024	20000821
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	DE 1999-19940494	A	19990826		
	WO 2000-EP8126	W	20000821		

OS MARPAT 134:178565
GI



I



II

AB Title compds. [I, II; R1 = H, Me, Et; R2 = H, Me; R3 = SH, hydroxyaminoacylalkylthio, alkyl; R4 = H, alkyl, Ph, PhCH2; n = 0-2; A = alkylene; X = SH, hydroxyaminoacylalkylthio; Q = atoms to form benzo, (anellated) thieno rings; R5 = H, Me, F, Cl, Br, MeS, etc.], were prepd. 2-Methyl-1,2-dihydro-5H-thiazolo[3,2-a]quinazoline-5-one hydrobromide (prepn. given) was refluxed 8 h with H2SO4 and HOAc in H2O to give 1-(2-mercaptopropyl)quinazoline-2,4-(1H,3H)-dione. The latter inhibited Clostridium histolyticum collagenase by 50% at 21.0 .mu.M. Drug formulations contg. 1-(3-mercaptopropyl)quinazolin-2,4-(1H,3H)-dione were given.

IT **13906-05-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of mercaptoalkylquinazolinediones and related compds. as inhibitors of matrix metalloproteinase)

RN 13906-05-3 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI) (CA

INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 8 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 2000:790502 CAPLUS
DN 133:350240
TI 1-Aminotriazolo[4,3-a]quinazolin-5-ones and -5-thiones inhibiting phosphodiesterase IV
IN Gaudilliere, Bernard; Lavalette, Remi; Andrianjara, Charles; Breuzard, Francine
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 197 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000066584	A1	20001109	WO 2000-FR1174	20000428
	W: AE, AG, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2792938	A1	20001103	FR 1999-5398	19990428
	FR 2792938	B1	20010706		
	BR 2000010072	A	20020205	BR 2000-10072	20000428
	EP 1177195	A1	20020206	EP 2000-967407	20000428
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002543199	T2	20021217	JP 2000-615614	20000428
	NO 2001005235	A	20011221	NO 2001-5235	20011026
PRAI	FR 1999-5398	A	19990428		
	WO 2000-FR1174	W	20000428		

OS MARPAT 133:350240
GI



I



II

AB Triazolo[4,3-a]quinazolin-5-ones and -5-thiones I and II [A1 = O, S; X1, X2 = H, OH, halogen, amino, NO2, SH, CN, alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, (un)substituted CO2H; R = (un)substituted alkyl, alkenyl, alkynyl, pyridylalkyl; R1, R2 = alkyl, aralkyl, cycloalkyl, cycloalkylalkyl; NR1R2 = heterocyclic] were prepd. for use as inhibitors of phosphodiesterase IV. Thus, I [A = O, R = (E)-cinnamyl, X1

= 7-Cl, X2 = H, NR1R2 = perhydroazepino, III] was obtained together with II [A = O, R = (E)-cinnamyl, X1 = 7-Cl, X2 = H, NR1R2 = perhydroazepino] by treating I [A = O, R = H, X1 = 7-Cl, X2 = H, NR1R2 = perhydroazepino] with (E)-cinnamyl bromide. III had an IC50 for PDE-4 inhibition of 0.054
.mu.M.

IT **305805-07-6 305805-17-8 305805-18-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(1-aminotriazolo[4,3-a]quinazolin-5-ones and -5-thiones inhibiting phosphodiesterase IV)

RN 305805-07-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-bromo-1-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 305805-17-8 CAPLUS
RN 305805-18-9 CAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 6-chloro-3-(phenylmethyl)-, 2-hydrazone (9CI)
(CA INDEX NAME)



IT **35977-17-4P 305804-86-8P 305804-89-1P**
305804-91-5P 305804-92-6P 305804-93-7P
305804-94-8P 305804-95-9P 305804-96-0P
305804-97-1P 305804-98-2P 305804-99-3P
305805-00-9P 305805-01-0P 305805-02-1P
305805-03-2P 305805-04-3P 305805-05-4P
305805-09-8P 305805-11-2P 305805-13-4P
305805-21-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(1-aminotriazolo[4,3-a]quinazolin-5-ones and -5-thiones inhibiting phosphodiesterase IV)

RN 35977-17-4 CAPLUS
CN 4(1H)-Quinazolinone, 6-bromo-2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI)
(CA INDEX NAME)



RN 305804-86-8 CAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 6-bromo-3-(phenylmethyl)-, 2-hydrazone (9CI)
(CA INDEX NAME)



RN 305804-89-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1,7-dichloro-4-(phenylmethyl)-
(9CI) (CA INDEX NAME)



RN 305804-91-5 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1,7-dibromo-4-(phenylmethyl)-
(9CI) (CA INDEX NAME)



RN 305804-92-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 1-(hexahydro-1H-azepin-1-yl)-
(9CI) (CA INDEX NAME)



RN 305804-93-7 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-bromo-1-(hexahydro-1H-azepin-
1-yl)- (9CI) (CA INDEX NAME)



RN 305804-94-8 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 1-(hexahydro-1H-azepin-1-
yl)-8-
methyl- (9CI) (CA INDEX NAME)



RN 305804-95-9 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 1,8-bis(hexahydro-1H-azepin-
1-
yl)- (9CI) (CA INDEX NAME)



RN 305804-96-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-bromo-1-(1-piperidinyl)-
(9CI) (CA INDEX NAME)



RN 305804-97-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-bromo-1-(1-pyrrolidinyl)-
(9CI) (CA INDEX NAME)



RN 305804-98-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-chloro-1-(hexahydro-1H-
azepin-1-yl)- (9CI) (CA INDEX NAME)



RN 305804-99-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 1-(1-pyrrolidinyl)- (9CI)
(CA
INDEX NAME)



RN 305805-00-9 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 1-(hexahydro-1H-azepin-1-yl)-7-
methyl- (9CI) (CA INDEX NAME)



RN 305805-01-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-methyl-1-(1-pyrrolidinyl)-
(9CI) (CA INDEX NAME)



RN 305805-02-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 1-(dimethylamino)-7-methyl-
(9CI) (CA INDEX NAME)



RN 305805-03-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 7-hydroxy-1-(1-piperidinyl)-
(9CI) (CA INDEX NAME)



RN 305805-04-3 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carbonitrile, 3,5-dihydro-5-oxo-1-(1-
pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305805-05-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazoline-7-carbonitrile, 1-(dimethylamino)-3,5-dihydro-5-oxo- (9CI) (CA INDEX NAME)



RN 305805-09-8 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-bromo-7-[[(4-methylphenyl)sulfonyl]oxy]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 305805-11-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 7-[[(4-

methylphenyl)sulfonyl]oxy]-1-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 305805-13-4 CAPLUS
CN Acetamide, N-[1-bromo-4,5-dihydro-5-oxo-4-(phenylmethyl)[1,2,4]triazolo[4,3-a]quinazolin-7-yl]- (9CI) (CA INDEX NAME)



RN 305805-21-4 CAPLUS
CN Acetamide, N-[3,5-dihydro-5-oxo-1-(1-pyrrolidinyl)[1,2,4]triazolo[4,3-a]quinazolin-7-yl]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 9 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1999:571561 CAPLUS
DN 131:310617
TI Novel triazolo[4,3-a]quinazolinone and bis-triazolo[4,3-a:4,3'-c]quinazolines: synthesis and antitoxoplasmosis effect
AU El-Tombary, Alaa A.; Ismail, Khadiga A.; Aboulwafa, Omaima M.; Omar, A.-Mohsen M. E.; El-Azzouni, Mervat Z.; El-Mansoury, Salwa T.
CS Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Alexandria, Alexandria, 21215, Egypt
SO Farmaco (1999), 54(7), 486-495
CODEN: FRMCE8; ISSN: 0014-827X
PB Elsevier Science S.A.
DT Journal
LA English
OS CASREACT 131:310617
AB Several quinazoline derivs. contg. substituted thiosemicarbazido and S-methylisothiosemicarbazido groups at the 2-position and at both the 2- and 4-positions were synthesized. Treatment of the S-methylthiosemicarbazides with morpholine or diethylamine did not give the corresponding guanidines. Instead, they underwent cyclodesulfurization into the condensed ring systems, [1,2,4]triazolo[4,3-a]quinazolinones and bis-[1,2,4]triazolo[4,3-a:4',3'-c]quinazolines. Evaluation of the products for antitoxoplasmosis effect by studying the ultrastructure morphol. of the organisms using SEM indicated their efficacy in causing structural deformity of Toxoplasma gondii. Such a deformity plays an important role in obstructing the entry of the organisms into host cells.
IT **247257-94-9P 247257-95-0P 247257-96-1P 247257-97-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reactant for prepn. of triazolo[4,3-a]quinazolinones)
RN 247257-94-9 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 1-(phenylamino)- (9CI) (CA INDEX NAME)



RN 247257-95-0 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 1-[(4-chlorophenyl)amino]- (9CI) (CA INDEX NAME)



RN 247257-96-1 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 1-[(4-methylphenyl)amino]- (9CI) (CA INDEX NAME)



RN 247257-97-2 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(3H)-one, 1-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 10 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1996:512480 CAPLUS
DN 125:221784
TI A simple preparation of 2-thioxo-4(3H)-quinazolinones
AU Lakhan, Ram; Banerjee, Rakesh K.
CS Department of Chemistry, Banaras Hindu University, Varanasi, 221 005, India
SO Indian Journal of Heterocyclic Chemistry (1996), 5(4), 315-316
CODEN: IJCHEI; ISSN: 0971-1627
PB Lucknow University, Dep. of Chemistry
DT Journal
LA English
OS CASREACT 125:221784
AB A simple method is described for the prepn. of 3-alkyl-2-thioxo-4(3H)-quinazolinones by the reaction of ring substituted anthranilic acids and ammonium or sodium N-alkyldithiocarbamates in ethanol. A plausible reaction mechanism is suggested for the formation of products.
IT **13906-05-3P 19857-32-0P 23070-25-9P**
35977-17-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 13906-05-3 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



RN 19857-32-0 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-6-iodo-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



RN 23070-25-9 CAPLUS
CN 4(1H)-Quinazolinone, 6-chloro-2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI)
(CA INDEX NAME)



RN 35977-17-4 CAPLUS
CN 4(1H)-Quinazolinone, 6-bromo-2,3-dihydro-3-(phenylmethyl)-2-thioxo-(9CI)
(CA INDEX NAME)



L14 ANSWER 11 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1991:642850 CAPLUS
DN 115:242850
TI Effects of solvent on the electronic absorption and fluorescence spectra of quinazolines, and determination of their ground and excited singlet-state dipole moments
AU Aaron, J. J.; Tine, A.; Gaye, M. D.; Parkanyi, C.; Boniface, C.; Bieze, T.
W. N.
CS Inst. Topol. Dyn. Syst., Univ. Paris 7, Paris, 75005, Fr.
SO Spectrochimica Acta, Part A: Molecular and Biomolecular Spectroscopy (1991), 47A(3-4), 419-30
CODEN: SAMCAS; ISSN: 0584-8539
DT Journal
LA English
AB The electronic absorption, and fluorescence excitation and emission spectra of 11 quinazolines were measured at room temp. (298 K) in several solvents of different polarities (cyclohexane, dioxane, ethyl ether, chloroform, ethylacetate, 1-butanol, 2-propanol, ethanol, methanol, acetonitrile, DMF and DMSO). The effects of the solvent upon the spectral properties are discussed. Exptl. ground-state dipole moments were measured for quinazolines and were used in combination with the spectral results to evaluate their 1st excited singlet-state dipole moments by means of the solvatochromic shift method. The theor. ground and excited singlet-state dipole moments for selected quinazolines were calcd. as a vector sum of the .pi.-component (obtained by the PPP method) and the .sigma.-component (obtained from .sigma.-bond moments). A reasonable agreement was obsd. between the exptl. and the theor. values. Excited singlet-state dipole moments are higher than the ground-state values for most quinazolines.
IT **13906-05-3**
RL: PRP (Properties)
(electronic absorption and fluorescence spectra of, ground and singlet-state dipole moment from, solvent effect in relation to)
RN 13906-05-3 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



L14 ANSWER 12 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1990:612014 CAPLUS
DN 113:212014
TI Preparation of (1H-azol-1-ylmethyl)quinolines, -quinazolines, and -quinoxalines as drugs
IN Freyne, Eddy Jean Edgard; Venet, Marc Gaston; Raeymaekers, Alfons Herman Margaretha; Sanz, Gerard Charles
PA Janssen Pharmaceutica N. V., Belg.
SO Eur. Pat. Appl., 106 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 371564	A2	19900606	EP 1989-203014	19891128
	EP 371564	A3	19910529		
	EP 371564	B1	19950712		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 5028606	A	19910702	US 1989-434957	19891113
	US 5037829	A	19910806	US 1989-435120	19891113
	CA 2002864	AA	19900529	CA 1989-2002864	19891114
	DK 8905994	A	19900530	DK 1989-5994	19891128
	DK 172748	B1	19990628		
	NO 8904734	A	19900530	NO 1989-4734	19891128
	NO 174509	B	19940207		
	NO 174509	C	19940518		
	AU 8945646	A1	19900607	AU 1989-45646	19891128
	AU 620946	B2	19920227		
	HU 52498	A2	19900728	HU 1989-6220	19891128
	HU 205106	B	19920330		
	ZA 8909076	A	19910731	ZA 1989-9076	19891128
	SU 1780536	A3	19921207	SU 1989-4742543	19891128
	IL 92486	A1	19930708	IL 1989-92486	19891128
	ES 2088889	T3	19961001	ES 1989-203014	19891128
	CN 1042912	A	19900613	CN 1989-108925	19891129
	CN 1033752	B	19970108		
	JP 02223579	A2	19900905	JP 1989-307793	19891129
	JP 2916181	B2	19990705		
	US 5151421	A	19920929	US 1991-672298	19910320
	US 5185346	A	19930209	US 1991-704746	19910523
	US 5268380	A	19931207	US 1992-973871	19921110
	US 5441954	A	19950815	US 1993-131817	19931005
	CN 1106004	A	19950802	CN 1994-117801	19941102
	CN 1036002	B	19971001		
	CN 1106005	A	19950802	CN 1994-117802	19941102
	CN 1036003	B	19971001		
	US 5612354	A	19970318	US 1995-409551	19950323
PRAI	GB 1988-27820	A	19881129		
	GB 1988-27821	A	19881129		
	GB 1988-27822	A	19881129		
	US 1989-434205	B2	19891113		
	US 1989-434957	A3	19891113		
	US 1991-704746	A3	19910523		
	US 1992-973871	A3	19921110		
	US 1993-131817	A3	19931005		

OS MARPAT 113:212014

GI For diagram(s), see printed CA Issue.

AB The title compds. [I; R = H, alkyl; X1:X2 = CH:CH, CH:N, N:CH; Y = H, alkyl, cycloalkyl, alkenyl, alkynyl, (un)substituted aryl, aralkyl; Z = (un)substituted (oxo)quinolinyl, (oxo- or thioxo)quinazolinyl, (oxo- or dioxo)quinoxalinyl] were prepd. as retinoic acid metab. inhibitors, aromatase inhibitors, etc. Thus, 3,4-dihydroquinolin-2(1H)-one was stirred 2 h at 70.degree. with BzCl in DMF contg. AlCl3 and the product reduced by NaBH4 to give hydroxymethylquinolinone II (R1 = Ph, R2 = OH). II (R1 = Me, R2 = OH) was stirred overnight with SOCl2 in THF and the product II (R1 = Me, R2 = Cl) stirred overnight at 60-70.degree. with 1H-imidazole in DMSO to give II (R1 = Me, R2 = imidazolo) which maintained plasma levels of i.v. administered all-trans-retinoic acid at .gtoreq.10 ng/mL in rats 2 h after oral administration of 40 mg/kg.

IT **130344-86-4P 130344-95-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and reaction of, in prepn. of retinoate metab. and aromatase inhibitors)

RN 130344-86-4 CAPLUS

CN 4(1H)-Quinazolinone, 6-benzoyl-2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



RN 130344-95-5 CAPLUS

CN 4(1H)-Quinazolinone, 2,3-dihydro-6-(hydroxyphenylmethyl)-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



IT **130345-35-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of, as retinoate metab. and aromatase inhibitor)

RN 130345-35-6 CAPLUS

CN 4(1H)-Quinazolinone, 2,3-dihydro-6-(1H-imidazol-1-ylphenylmethyl)-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



L14 ANSWER 13 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1990:552804 CAPLUS
DN 113:152804
TI Antilipidemic agents. III. Synthesis of some heterocyclic derivatives of
.beta.-sitosterol
AU Habib, N. S.; Khalil, M. A.
CS Fac. Pharm., Univ. Alexandria, Alexandria, Egypt
SO Archiv der Pharmazie (Weinheim, Germany) (1990), 323(7), 401-4
CODEN: ARPMAS; ISSN: 0365-6233
DT Journal
LA English
GI



I

AB Four novel series of heterocyclic derivs. of .beta.-sitosterol were prepd.
by the reaction of 3-.beta.-sitosterol hemisuccinate with SOCl2 then with
thiols, amines or phenols. The antilipemic activity of esters I (R =
5-methyl-1,3,4-thiadiazol-2-ylamino, 8-quinolyloxy) is comparable to that
of .beta.-sitosterol.
IT **13906-05-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with sitosterol hemisuccinate)
RN 13906-05-3 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



L14 ANSWER 14 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1988:492925 CAPLUS
DN 109:92925
TI A facile preparation of 3-substituted 2-thioxotetrahydroquinazolin-4-ones
by the reaction of anthranilamide with isothiocyanates
AU Chan, Chao Han; Shish, Fang Jy; Liu, Kang Chien; Chern, Ji Wang
CS Sch. Pharm., Natl. Def. Med. Cent., Taipei, 10700, Taiwan
SO Heterocycles (1987), 26(12), 3193-6
CODEN: HTCYAM; ISSN: 0385-5414
DT Journal
LA English
OS CASREACT 109:92925
GI



II

AB Mixts. of 2-H2NC6H4CONH2 (I) and RNCS (R = alkyl, PhCH2, 2,6-Cl2C6H3) in MeCN gave thioxotetrahydroquinazolinones II. I also reacted with BzNCS to give 2-[BzNHC(S)NH]C6H4CONH2; the latter was stirred with NH3 to give II (R = H).
IT **13906-05-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 13906-05-3 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



L14 ANSWER 15 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1988:186686 CAPLUS
DN 108:186686
TI Acylation of 2-thioxoquinazolones-4: formation of 2-(acylthio)quinazolones-4
AU Yun, L. M.; Yangibaev, S.; Alekseeva, V. Ya.; V'yunov, K. A.; Shakhidoyatov, Kh. M.
CS Inst. Khim. Rastit. Veshchestv, Tashkent, USSR
SO Khimiya Geterotsiklicheskikh Soedinenii (1987), (8), 1095-7
CODEN: KGSSAQ; ISSN: 0453-8234
DT Journal
LA Russian
OS CASREACT 108:186686
GI


I

II

AB Acylation of 2-thioxo-4-quinazolinones I (R = H, Me) by R1COCl (R1 = Ph, substituted Ph) in DMF contg. Et3N gave 24-60% acylthio derivs. II.
IT **113580-76-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 113580-76-0 CAPLUS
CN 4(1H)-Quinazolinone, 3-benzoyl-2,3-dihydro-2-thioxo- (9CI) (CA INDEX NAME)



L14 ANSWER 16 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1987:628515 CAPLUS
DN 107:228515
TI Studies of 4(3H)-quinazolinone derivatives as antimalarials
AU Lakhan, Ram; Singh, Om Prakash; Singh, R. L.
CS Fac. Sci., Banaras Hindu Univ., Varanasi, 221 005, India
SO Journal of the Indian Chemical Society (1987), 64(5), 316-18
CODEN: JICSAH; ISSN: 0019-4522
DT Journal
LA English
OS CASREACT 107:228515
GI



I

AB 4(3H)-Quinazolinones [I, R = Me, Et or benzyl, R1 = H, Et, iso-Pr, or Ph;
R2 = H, Et, iso-Pr or Me and R1R2 = (CH2)5] were prepd. by the alkylation
of Na salts of the corresponding 2-thio-3-alkyl(aryl)-6-iodo-4(3H)-
quinazolinones with the appropriate 2-(N-substituted or N,N-disubstituted
amino)ethyl bromide-HBr salts. I were screened for antimalarial activity
in mice infected with Plasmodium berghei, and found inactive at 1 quinine
equiv. of the dosage.
IT **19857-32-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(S-alkylation of, by aminoethyl bromides)
RN 19857-32-0 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-6-iodo-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



L14 ANSWER 17 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1983:594989 CAPLUS
DN 99:194989
TI Triazoloquinazolones and their salts, intermediates for preparing them, their use as medicines and compositions containing them
IN Tully, Wilfred Roger; Westwood, Robert; Rowlands, David Alun; Clements-Jewery, Stephen
PA Roussel-UCLAF , Fr.
SO Eur. Pat. Appl., 39 pp.
CODEN: EPXXDW
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 76199	A2	19830406	EP 1982-401697	19820920
	EP 76199	A3	19840321		
	EP 76199	B1	19861230		
	R: AT, BE, CH, DE, FR, IT, LI, LU, NL, SE				
	IL 66835	A1	19880531	IL 1982-66835	19820917
	ZA 8206891	A	19831026	ZA 1982-6891	19820920
	AT 24509	E	19870115	AT 1982-401697	19820920
	US 4472400	A	19840918	US 1982-420798	19820921
	DK 8204206	A	19830325	DK 1982-4206	19820922
	DK 160308	B	19910225		
	DK 160308	C	19910729		
	AU 8288623	A1	19830331	AU 1982-88623	19820922
	AU 554959	B2	19860911		
	FI 8203278	A	19830325	FI 1982-3278	19820923
	FI 73435	B	19870630		
	FI 73435	C	19871009		
	GB 2108495	A1	19830518	GB 1982-27126	19820923
	GB 2108495	B2	19850724		
	ES 515904	A1	19831016	ES 1982-515904	19820923
	CA 1193597	A1	19850917	CA 1982-412016	19820923
	JP 58065292	A2	19830418	JP 1982-165197	19820924
	JP 03022389	B4	19910326		
	HU 26739	O	19830928	HU 1982-3090	19820924
	HU 186975	B	19851028		
PRAI	GB 1981-28875		19810924		
	EP 1982-401697		19820920		

OS CASREACT 99:194989
GI



I

AB Triazoloquinazolones I [R, R1 = H, halo, alkyl, alkoxy, NO2; R2 = alkyl, cycloalkyl, aryl, aralkyl; R3 = amino; X = (CH2)1-31, CHMe] were prepd. Thus, 2-H2NC6H4CO2Me was treated with PrNCO to give 2-MeO2CC6H4NHCONHPr which was cyclized to 3-propyl-2,4-quinazolinedione. Enol chlorination of the dione and reaction with N2H4 gave 2-hydrazino-3-propyl-4-quinazolinone which was cyclized with ClCH2COCl to give I (R = R1 = H, R2 = Pr, R3 = Cl, X = CH2). Amination of the latter compd. gave I (R = R1 = H, R2 = Pr, R3 = piperidino, X = CH2) which had a ED50 of 0.12 mg/kg i.v. against histamine-induced bronchial spasms in guinea pigs.

IT **74395-78-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and cyclization of, with chloroacetyl chloride)

RN 74395-78-1 CAPLUS

CN 2,4(1H,3H)-Quinazolinedione, 3-(phenylmethyl)-, 2-hydrazone (9CI) (CA INDEX NAME)



IT **13906-05-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, with hydrazine)

RN 13906-05-3 CAPLUS

CN 4(1H)-Quinazolinone, 2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



L14 ANSWER 18 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1983:470757 CAPLUS
DN 99:70757
TI 1,4,7,9-Differently substituted 4,5-dihydro-s-triazolo[4,3-a]quinazolin-5-ones
IN Kottke, Karl; Kuehmstedt, Hans; Hagen, Volker; Renner, Helga; Schnitzler, Stephan
PA Akademie der Wissenschaften der DDR, Ger. Dem. Rep.
SO Ger. (East), 27 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DD 158549	Z	19830119	DD 1981-229905	19810513
PRAI DD 1981-229905		19810513		

GI



I

AB Triazoloquinazolinones I [R, R1 = H, alkyl, halo, alkoxy, alkylthio; R2 = H, OH, SH, alkoxy, alkylthio, amino, (un)substituted alkyl, aryl, etc.; R3 = H, alkyl, (un)substituted aryl] were prepd. Thus, 3-(3-methylphenyl-2-hydrazino-4(3H)quinazolinolinone was cyclocondensed with HCO2H to give 92% I (R = R1 = H, R2 = OH, R3 = 3-MeC6H4) (II). II gave 30% inhibition of passive cutaneous anaphylaxis in rats.

IT **86506-91-4P 86506-92-5P 86506-93-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 86506-91-4 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 4-(4-chlorophenyl)-1-(ethylsulfonyl)- (9CI) (CA INDEX NAME)



RN 86506-92-5 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 4-(4-bromophenyl)-1-(ethylsulfonyl)- (9CI) (CA INDEX NAME)



RN 86506-93-6 CAPLUS
CN [1,2,4]Triazolo[4,3-a]quinazolin-5(4H)-one, 1-(ethylsulfonyl)-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



L14 ANSWER 19 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1982:582338 CAPLUS
DN 97:182338
TI Synthesis and antimicrobial activity of substituted 4(3H)-quinazolones: (II)
AU Misra, Hemant K.; Sen Gupta, Anil K.
CS Chem. Dep., Lucknow Univ., Lucknow, 226 007, India
SO European Journal of Medicinal Chemistry (1982), 17(3), 216-18
CODEN: EJMCA5; ISSN: 0009-4374
DT Journal
LA English
OS CASREACT 97:182338
GI



I



II



III

AB The quinazolinones I [R = cyclohexyl, 2-cyclohexylethyl; R1 = (un)substituted Ph, PhCH2, cyclohexyl; R2 = H, Br] were prepd. by treating the mercaptoquinazolines II with the thiadiazolylchloroacetamides III. The bactericidal and fungicidal activity of I was evaluated against several test organisms. The presence of R1 = p-MeOC6H4 and PhCH2 enhanced the fungicidal activity of I.

IT **18730-39-7 35977-17-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with (chloroacetamido)thiadiazoles)

RN 18730-39-7 CAPLUS
CN 4(1H)-Quinazolinone, 6,8-dibromo-2,3-dihydro-3-(phenylmethyl)-2-thioxo-(9CI) (CA INDEX NAME)



RN 35977-17-4 CAPLUS
CN 4(1H)-Quinazolinone, 6-bromo-2,3-dihydro-3-(phenylmethyl)-2-thioxo-(9CI)(CA INDEX NAME)



L14 ANSWER 20 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1982:467748 CAPLUS
DN 97:67748
TI Synthesis and pesticidal activities of some new substituted 3H-quinazolin-4-one derivatives. Part XVIII
AU Misra, Hemant K.; Sen Gupta, Anil K.
CS Chem. Dep., Lucknow Univ., Lucknow, 226007, India
SO Pesticide Science (1982), 13(2), 177-82
CODEN: PSSCBG; ISSN: 0031-613X
DT Journal
LA English
OS CASREACT 97:67748
GI



I

AB The synthesis of 20 substituted 3H-quinazolin-4-one derivs. (I; X = H or Br; R1 = benzyl, cyclohexyl, 4-methoxyphenyl, o-tolyl, or p-tolyl; R2 = Ph or 4-chlorophenyl; and R3 = H or Me) is described, and their antibacterial, anti-acetylcholinesterase [9000-81-1], and insecticidal activities were detd. and related to their structure.

IT **18730-39-7P 35977-17-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. and reaction of, with arylchloroacetylaminomethylthiazoles)

RN 18730-39-7 CAPLUS
CN 4(1H)-Quinazolinone, 6,8-dibromo-2,3-dihydro-3-(phenylmethyl)-2-thioxo-(9CI) (CA INDEX NAME)



RN 35977-17-4 CAPLUS
CN 4(1H)-Quinazolinone, 6-bromo-2,3-dihydro-3-(phenylmethyl)-2-thioxo-(9CI)(CA INDEX NAME)



L14 ANSWER 21 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1981:407238 CAPLUS
DN 95:7238
TI Studies on thioquinazolinones and synthesis of 9-iodo-3,4-diphenyl [1,2,4,5]tetrazepino[3,2-b]quinazolin-7(1H)-one
AU Chaurasia, M. R.; Sharma, Surendra K.
CS Dep. Chem., D.A.V. Coll., Dehra Dun, India
SO Heterocycles (1981), 16(4), 621-9
CODEN: HTCYAM; ISSN: 0385-5414
DT Journal
LA English
GI



I



II



III



IV



V

AB Sulfuration of quinazolinone I (X = O) by P2S5 gave 81% I (X = S), which was treated with 1-(chloroacetyl)piperidine and Br(CH2)2NEt2 to give 85% II (R = piperidinocarbonylmethyl) and 76% II [R = (CH2)2NEt2], resp. Hydrolysis of II gave I (X = O). Treating III (R = PhCH2) with MeI in alc. NaOH gave 61% IV (R = Me, R1 = MeS) which was refluxed with N2H4 to give 78% IV (R = NH2, R1 = NHNH2). The latter was cyclocondensed with benzil to give 81% V.
IT **18730-39-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
RACT
(Reactant or reagent)
(prepn. and reactions of)
RN 18730-39-7 CAPLUS
CN 4(1H)-Quinazolinone, 6,8-dibromo-2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



L14 ANSWER 22 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1981:175041 CAPLUS
DN 94:175041
TI Synthesis of some novel quinazolone thiosemicarbazide and thiazoline derivatives for potential antimicrobial activity
AU Omar, A. Mohsen M. E.; El-Dine, S. A. Shams; Ghobashy, A. A.; Khalil, M. A.
CS Fac. Pharm., Univ. Alexandria, Alexandria, Egypt
SO European Journal of Medicinal Chemistry (1981), 16(1), 77-80
CODEN: EJMCA5; ISSN: 0009-4374
DT Journal
LA English
GI


I

II

AB Thiosemicarbazides I (R1 = allyl, optionally substituted Ph, PhCH2, R2 = optionally substituted Ph, PhCH2, allyl, Bu), possessing significant gram-pos. bactericidal activity, were prepd. in 60-92% yields from 4-oxoquinazoline-2-thiones by reaction with N2H4.H2O, followed by addn. of R2NCS. Cyclocondensation of I with R3COCH2Br (R3 = Ph, 4-ClC6H4) gave 63-85% II (R1,R2 as above).

IT **74395-78-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and addn. of, with isothiocyanates)
RN 74395-78-1 CAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 3-(phenylmethyl)-, 2-hydrazone (9CI) (CA INDEX NAME)



IT **13906-05-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with hydrazine hydrate)
RN 13906-05-3 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



L14 ANSWER 23 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1981:139743 CAPLUS
DN 94:139743
TI Synthesis and evaluation of substituted quinazolone derivatives for antibacterial, antifungal, and antiacetylcholinesterase activities
AU Gupta, Anil K. Sen; Misra, Hemant K.
CS Dep. Chem., Univ. Lucknow, Lucknow, 226007, India
SO Journal of Pharmaceutical Sciences (1980), 69(11), 1313-17
CODEN: JPMSAE; ISSN: 0022-3549
DT Journal
LA English
GI



I

AB The thiadiazolylcarbamoylmethylthioquinazolones I (R = H, Br; R1 = PhCH2, o-EtC6H4, cyclohexyl, p-MeOC6H4; R2 = Me, Et, Pr) were prepd. by reaction of the corresponding quinazoline with the (chloroacetamido)thiadiazole. I were screened for antibacterial, antifungal, and antiacetylcholinesterase activities in vitro. Most of the compds. exhibited significant biol. activity. The relation between their biol. activity and chem. structure was studied.

IT **18730-39-7 35977-17-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with (chloroacetamido)thiadiazoles)

RN 18730-39-7 CAPLUS
CN 4(1H)-Quinazolinone, 6,8-dibromo-2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



RN 35977-17-4 CAPLUS
CN 4(1H)-Quinazolinone, 6-bromo-2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



L14 ANSWER 24 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1980:472071 CAPLUS
DN 93:72071
TI Steroidal derivatives. Part 3: Synthesis of some novel steroidal hydrazones containing theophylline and quinazolone moieties
AU Omar, A. Mohsen M. E.; Ashour, F. A.
CS Fac. Pharm., Univ. Alexandria, Alexandria, Egypt
SO Pharmazie (1979), 34(11), 747-8
CODEN: PHARAT; ISSN: 0031-7144
DT Journal
LA English
GI



I


II


=Q


=Q1

AB Steroidal hydrazones I and II [R = H, Me; R1 = Q, Q1 (R4 = Bu, PhCH2, MeC6H4, ClC6H4, BrC6H4); R2 = H, Ac, EtCO; R3 = H, Me] were prepd. by condensation of theophylline-7-acetohydrazide and 2-hydrazinoquinazolones with estrone, estrone Me ether, 19-nortestosterone propionate, testosterone, and testosterone acetate.

IT **74395-78-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation reaction of, with oxo steroids)

RN 74395-78-1 CAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 3-(phenylmethyl)-, 2-hydrazone (9CI) (CA INDEX NAME)



L14 ANSWER 25 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1979:456950 CAPLUS
DN 91:56950
TI 2-(Mono- and dinitrophenylthio)-3-substituted-4(3H)-quinazolinones: potential sedative-hypnotic agents
AU Shafik, Ragab M.; Hazzaa, Aly A. B.; Habib, Nargues S.
CS Fac. Pharm., Univ. Alexandria, Alexandria, Egypt
SO Pharmazie (1979), 34(3), 148-50
CODEN: PHARAT; ISSN: 0031-7144
DT Journal
LA English
GI



I

AB Quinazolinones I (R = Bu, CH2Ph, Ph, 2-MeC6H4, 3-MeC6H4, 4-MeC6H4, 2-MeOC6H4, 4-ClC6H4; R1 = NO2, R2 = H, NO2; R1 = H, R2 = NO2) were prepd.
by treating 2-H2NC6H4CO2H with RNCS and treating quinazolinethiones with KOH and halonitrobenzenes.
IT **13906-05-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. and reaction of, with halonitrobenzenes)
RN 13906-05-3 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



L14 ANSWER 26 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1978:597451 CAPLUS
DN 89:197451
TI Studies on 2-N-isobutyl/isopropyl/carbamoylmethylthio-3-aryl-4(3H)-quinazolinones
AU Bhargava, P. N.; Prakash, Shree
CS Dep. Chem., Banaras Hindu Univ., Varanasi, India
SO Journal of the Indian Chemical Society (1977), 54(9), 881-5
CODEN: JICSAH; ISSN: 0019-4522
DT Journal
LA English
GI



I

AB The quinazolinones I (R = o-MeC6H4, Ph, p-ClC6H4, PhCH2; R1 = Me2CHCH2, Me2CH) were prepd. by the reaction of 2-mercapto-3-aryl-4(3H)-quinazolinones and N-isobutyl(or isopropyl)-2-chloroacetamide in EtOH at room temp. I were tested as bactericides and fungicides but were inactive.

IT **13906-05-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with isopropylchloroacetamide)

RN 13906-05-3 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



L14 ANSWER 27 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1978:509345 CAPLUS
DN 89:109345
TI Synthesis of some new 6,8-diiodo-S-substituted-2-thio-3-aryl(or alkyl)-4(3H)-quinazolinones
AU Bhargava, P. N.; Singh, S. N.
CS Fac. Sci., Banaras Hindu Univ., Varanasi, India
SO Journal of Scientific Research of the Banaras Hindu University (1976), 26(1), 27-32
CODEN: JSRBA9; ISSN: 0447-9483
DT Journal
LA English
GI



I

AB Substituted 2-mercapto-4(3H)-quinazolinones I (R = Ph or Ph substituted by Me, Cl, MeO or EtO groups, Me, Et, Bu, PhCH2; R1 = Et, Pr, p-O2NC6H4) were prepd. by cyclocondensation of 3,5,2-I2(H2N)C6H3CO2H with RNCS followed by S-alkylation or S-arylation of the resulting I (R1 = H).

IT **37802-58-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and S-alkylation of)

RN 37802-58-7 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-6,8-diiodo-3-(phenylmethyl)-2-thioxo-(9CI) (CA INDEX NAME)



L14 ANSWER 28 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1977:439401 CAPLUS
DN 87:39401
TI Synthesis of S-substituted-2-mercapto-3-aryl (or aralkyl)-4 (3H) quinazolinones: their CNS and antimicrobial activity
AU Bhargava, P. N.; Prakash, Shree
CS Dep. Chem., Banaras Hindu Univ., Banaras, India
SO Indian Journal of Pharmacy (1977), 39(1), 18-20
CODEN: IJPAAO; ISSN: 0019-5472
DT Journal
LA English
GI



I

AB Quinazolinylthioacetamides I (R = Ph, 2-MeC6H4, 4-ClC6H4, 4-MeOC6H4, 4-EtOC6H4, R1 = CH2CHMe2, CH2Ph; R = 4-MeC6H4, R1 = CH2CHMe2; R = 3-MeC6H4, PhCH2, R1 = CH2Ph) were obtained by treating quinazolinethiols with ClCH2CONR12. I increased spontaneous motor activity in mice at 600 mg/kg but had no bactericidal or fungicidal activity.
IT **13906-05-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with chloroacetamides)
RN 13906-05-3 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



L14 ANSWER 29 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1976:463017 CAPLUS
DN 85:63017
TI A new method for the preparation of 1H,3H-quinazoline-2,4-diones and 1H,3H-quinazoline-2-thio-4-ones
AU Singh, Amrik; Bhandari, Brij M.
CS Chem. Dep., Guru Nanak Univ., Amritsar, India
SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1976), 14B(1), 67-8
CODEN: IJSBDB; ISSN: 0376-4699
DT Journal
LA English
GI



I

AB O-H2NC6H4CONHR (R = H, Me, Et, Pr, PhCH2, H2C:CHCH2, p-MeC6H4) on condensation with R1NCS (R1 = Me, H2C:CHCH2) gave the quinazolinones I (X = S, R = R1 = Me, CH2:CHCH2). Condensation with PhNCS and PhNCO gave the corresponding phenylthioureas and phenylureas which when heated above their m.p. gave I (R = Ph, H, Me, Et, Pr, PhCH2, H2C:CHCH2, p-MeC6H4; X = O, S).

IT **13906-05-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 13906-05-3 CAPLUS

CN 4(1H)-Quinazolinone, 2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



L14 ANSWER 30 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1976:59359 CAPLUS
DN 84:59359
TI Quinazolones derivatives
AU Shyam, Radhey; Tiwari, I. C.
CS Fac. Sci., Banaras Hindu Univ., Banaras, India
SO Current Science (1975), 44(16), 572-4
CODEN: CUSCAM; ISSN: 0011-3891
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB Fifteen quinazolones (I; R = Et2NCH2CH2, EtO2CCH2; R1 = Ph, substituted phenyl, PhCH2) were prepd. by reaction of I (R = H, R1 as before) with an equiv. amt. of Et2NCH2CH2Cl or ClCH2CO2Et in alc. NaOH soln. at room temp.
IT **35977-17-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with (diethylamino)ethyl chloride)
RN 35977-17-4 CAPLUS
CN 4(1H)-Quinazolinone, 6-bromo-2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI)
(CA INDEX NAME)



L14 ANSWER 31 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1975:43326 CAPLUS
DN 82:43326
TI Synthesis of 4(3H)-quinazolone derivatives
AU Bhargava, P. N.; Shyam, Radhey
CS Dep. Chem., Banaras Hindu Univ., Varnasi, India
SO Indian Journal of Chemistry (1974), 12(7), 779-80
CODEN: IJOCAP; ISSN: 0019-5103
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB Quinazolones (I, R = Ph, substituted Ph; R1 = Pr, Bu were prepd. by the reaction of 6-bromo-2-thio-3-aryl-4(3H)-quinazolones with N,N-dipropyl(or dibutyl)-2-chloroacetamides in the presence of 10% ethanolic NaOH at room temp. The compds. possess no remarkable pharmacol. or microbiol. activities.
IT **35977-17-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with chloroacetamides)
RN 35977-17-4 CAPLUS
CN 4(1H)-Quinazolinone, 6-bromo-2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI)
(CA INDEX NAME)



L14 ANSWER 32 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1974:505430 CAPLUS
DN 81:105430
TI Sulfur-containing derivatives analogous to benzoyleneurea
AU Lespagnol, A.; Lespagnol, C.; Bernier, J. L.
CS Lab. Pharm. Chim., INSERM, Lille, Fr.
SO Annales Pharmaceutiques Francaises (1974), 32(2), 125-32
CODEN: APFRAD; ISSN: 0003-4509
DT Journal
LA French
GI For diagram(s), see printed CA Issue.
AB Quinazolinones I (X = O, R = H, R1 = Et, Bu, allyl, Ph, p-FC6H4, PhCH2, PhCH2CH2) were prepd. in 72-100% yield by treating .omicron.-H2NC6H4CO2Me with RNCS. I (X = O; R = CH2CO2H, R1 = Ph; R = CH2CH2NEt2.HCl, R1 = Et) were obtained by alkylating I (R = H) with RCl. I (X = S, R = H, R1 = Et, allyl, Ph, PhCH2, PhCH2CH2) were prepd. in 40-61% yield by treating I (X = O) with P2S5. I (X = NH, R = H, R1 = Ph, p-FC6H4, PhCH2, allyl) were prepd. in 45-55% yield by treating .omicron.-H2NC6H4CN with RNCS. Only I (X = NH, R = H, R1 = Ph, p-FC6H4) showed antifolic activity against Streptococcus fecalis at 200 .gamma./ml.
IT **13906-05-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and sulfurization of)
RN 13906-05-3 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



L14 ANSWER 33 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1974:477867 CAPLUS
DN 81:77867
TI S-substituted 2-mercapto-3-aryl(or alkyl)-4(3H)-quinazolones
AU Bhargava, P. N.; Tiwari, Ishwar C.
CS Dep. Chem., Banaras Hindu Univ., Banaras, India
SO Indian Journal of Chemistry (1974), 12(2), 223-4
CODEN: IJOCAP; ISSN: 0019-5103
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB (R = p-MeC6H4, m-ClC6H4, p-ClC6H4, p-MeOC6H4 p-EtOC6H4, CH2Ph, Et; R1 = Pr, Bu) were pred. for testing as antimalarials and ataractics by treating the mercaptoquinazolones with ClCH2CONR12.
IT **13906-05-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with chloroacetamides)
RN 13906-05-3 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



L14 ANSWER 34 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1974:146101 CAPLUS
DN 80:146101
TI New S-substituted-2-thio-3-aryl(or alkyl)-4(3H)quinazolones as antituberculars
AU Bhargava, P. N.; Singh, S. N.
CS Dep. Chem., Banaras Hindu Univ., Varanasi, India
SO Egyptian Journal of Chemistry (1972), 15(5), 495-9
CODEN: EGJCA3; ISSN: 0449-2285
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB The quinazolinones I (R = Ph, o-, m-, and p-MeC6H4, m- and p-ClC6H4, p-MeOC6H4, p-EtOC6H4, Me, Et, Bu, PhCH2; R1 = Bu, PhCH2; R2 = iodo) were prepd. by alkylation of I (R1 = H). I (R = o-, m-, and p-MeC6H4, m- and p-ClC6H4, p-MeOC6H4, p-EtOC6H4, PhCH2, Et, Bu, Ph; R1 = Et2NCH2, 2-pyrrolidinoethyl, 2-piperidinoethyl; R2 = H) were prepd. by treating
II
(R2 = H) with chloroethylamines. At 100 .mu.g/ml I (R = p-EtOC6H4, p-ClC6H4; R1 = 2-piperidinoethyl R2 = H) inhibited Mycobacterium tuberculosis H37Rv.
IT **37802-58-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(alkylation of)
RN 37802-58-7 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-6,8-diiodo-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



IT **13906-05-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(aminoethylation of)
RN 13906-05-3 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



L14 ANSWER 35 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1972:539955 CAPLUS
DN 77:139955
TI 2-Mercapto-3-arylquinazolin-4-ones
AU Kozhevnikov, Yu. V.; Petyunin, P. A.; Berdinskii, I. S.
CS USSR
SO Uch. Zap. Perm. Univ. (1970), No. 229, 270-3
From: Ref. Zh., Khim. 1971, Abstr. No. 23Zh416
DT Journal
LA Russian
GI For diagram(s), see printed CA Issue.
AB Anthranilanilide (0.02 mole) and 0.04 mole thiourea was heated 1 hr at 185-90.degree. to give 80% of a title quinazolinone (I, R = Ph). Other I prepd. were as follows (R and % yield given): o-tolyl, 51; m-tolyl, 74; p-tolyl, 83; benzyl, 45; p-ClC6H4, 87; p-MeOC6H4, 53; m-ClC6H4, 58; and p-BrC6H4, 60.
IT **1029-04-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 1029-04-5 CAPLUS

L14 ANSWER 36 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1972:514350 CAPLUS
DN 77:114350
TI New 6:8-diiodo-S-substituted-2-thio-3-aryl (or alkyl)-4(3H)-quinazolones
AU Bhargava, P. N.; Singh, Janardan
CS Dep. Chem., Banaras Hindu Univ., Varanasi, India
SO Journal of the Indian Chemical Society (1972), 49(6), 633-5
CODEN: JICSAH; ISSN: 0019-4522
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB Refluxing RNCS (R = Ph, o-, m-, and p-MeC6H4, p-MeOC6H4, p-EtOC6H4, p-ClC6H4, PhCH2, Bu) and 3,5,2-I2(H2N)C6H2CO2H in abs. EtOH for 6 hr gave quinazolone derivs. (I, R1 = H). These derivs. reacted with R1I (R1 = n-C5H11, Me2CHCH2CH2, o-O2NC6H4CH2) to give 24 of the corresponding I.
IT **37802-58-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 37802-58-7 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-6,8-diiodo-3-(phenylmethyl)-2-thioxo-(9CI) (CA INDEX NAME)



L14 ANSWER 37 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1972:514347 CAPLUS
DN 77:114347
TI Quinazolines. IV. Synthesis of 2-alkyl-3-alkyl(aralkyl)aryl-4(3H)-benzo(g)quinazolinones and 2-mercapto-3-aryl(alkyl)alkyl-4(3H)-benzo(g)quinazolinones
AU Satpanthi, P. S.; Trivedi, J. P.
CS Chem. Dep., Gujarat Univ., Ahmedabad, India
SO Journal of the Indian Chemical Society (1972), 49(6), 605-9
CODEN: JICSAH; ISSN: 0019-4522
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB The benzoquinazolinone derivs. (I, R = Me, Et; R1 = Bu, Me(CH2)4, Me(CH2)5, Ph, o, m-, p-ClC6H4, o-, m-, p-tolyl, o-, p-MeOC6H4, p-BrC6H4, p-IC6H4, PhCH2, o-, m-, p-ClC6H4CH2, o-, m-, p-MeC6H4CH2, p-BrC6H4CH2, 2,4-, 2,5-, 3,4-Me2C6H3-CH2, 2,4-Cl2C6H3CH2, o-, m-, p-O2NC6H4, .alpha.-naphthyl, .beta.-naphthyl) were prepd. in 50-65% yield by treating the 3-acylamino-2-naphthoic acid with R1NH2 and PCl3. I (R = SH) were obtained by treating 3-amino-2-naphthoic acid with R1NCS and were methylated to I (R = SMe). 3-Propionamido-2-naphthoic acid was prepd. by acylating 3-amino-2-naphthoic acid with (EtCO)2O and EtCO2Na.
IT **37805-05-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 37805-05-3 CAPLUS
CN Benzo[g]quinazolin-4(1H)-one, 2,3-dihydro-3-(phenylmethyl)-2-thioxo-(9CI)
(CA INDEX NAME)



L14 ANSWER 38 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1972:99606 CAPLUS
DN 76:99606
TI Quinazolines. III. Synthesis of 2-alkyl-3-aralkyl-4-(3H)- and 2-mercapto-3-aralkyl(alkyl)-4(3H)-quinazolinones
AU Satpanthi, P. S.; Trivedi, J. P.
CS St. Xavier's Coll., Ahmedabad, India
SO Journal of the Indian Chemical Society (1971), 48(11), 1021-6
CODEN: JICSAH; ISSN: 0019-4522
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB Fifteen quinazolinones (I) (e.g., I, R = Me, R1 = H, R2 = o-ClC6H4) were prepd. in 50-5% yield by treatment of o-RCON-HC6H4CO2H with R1R2CHNH2 and PCl3 (or POCl3). Twenty thioxoquinazolinones (II) (e.g., II, R = Bz) were prepd. in 50-65% yield by condensation of 5,2-X(H2N)C6H3CO2H (X = H, Br, iodo) with RNCS. II were treated with MeI to give 20 (methylthio)quinazolinones (III) (e.g., III, R = Bz).
IT **13906-05-3P 19857-32-0P 35977-17-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 13906-05-3 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



RN 19857-32-0 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-6-iodo-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



RN 35977-17-4 CAPLUS
CN 4(1H)-Quinazolinone, 6-bromo-2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI)(CA INDEX NAME)



L14 ANSWER 39 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1969:422098 CAPLUS
DN 71:22098
TI Synthesis of some new 6-chloro-S-substituted 2-mercapto-3-aryl(or -alkyl-)4(3H)-quinazolones as antimalarials
AU Bhargava, Prithwi N.; Choubey, V. N.
CS Banaras Hindu Univ., Varanasi, India
SO Journal of Medicinal Chemistry (1969), 12, 553-4
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
AB The synthesis of 6-chloro-2-mercapto-3-aryl- (or -alkyl-) 4(3H)-quinazolinones and their -S-substituted derivs. (I) from 5-chloroanthranilic acid, aryl (or alkyl) isothiocyanates, and alkyl halides was investigated.
IT **23070-25-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 23070-25-9 CAPLUS
CN 4(1H)-Quinazolinone, 6-chloro-2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI)
(CA INDEX NAME)



L14 ANSWER 40 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1969:47398 CAPLUS
DN 70:47398
TI Drugs acting on central nervous system: syntheses of 2-substituted and 2,3-disubstituted benzo[6,7]quinazolin-4-ones
AU Gupta, Chhitar M.; Bhaduri, Amiya P.; Khanna, Nandoo M.
CS Cent. Drug Res. Inst., Lucknow, India
SO Indian Journal of Chemistry (1968), 6(11), 621-3
CODEN: IJOCAP; ISSN: 0019-5103
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB A series of 2-substituted and 2,3-disubstituted benzo[6,7]quinazolin-4-ones (I) were synthesized as possible central nervous system (CNS) depressants. The 2-substituted products, viz. hydrazino, phenylhydrazino and amino, were obtained in 50-70% yield by the reaction (5-6 hrs. at 120.degree.) of 1 mole 2-ethylthiobenzo[6,7]quinazolin-4-one (II) with 3 moles of the required base (N2H4, PhNHNH2, primary and secondary amines). The required II were prepd. as follows. A mixt. of 14 g. 3-amino-2-naphthoic acid (II) and 11.9 g. ben-zoylisothiocyanate in 300 ml. dry Me2CO was refluxed 5 hrs. to yield 21.7 g. 2-mercaptobenzo[6,7]quinazolin-4-one (III). III (16.6 g.) on heating 1 hr. (steam bath) with 100 ml. 10% NaOH and subsequent acidification afforded 11.1 g. 2-mercaptobenzo-[6,7]quinazolin-4-one (IV). IV (2.3 g.) followed by 1 ml. EtI was added to a soln. of 0.23 g. Na in 20 ml. EtOH and the mixt. refluxed 3 hrs. to yield 2.9 g. II. 2-Alkyl- or arylalkylthio-3-phenylbenzo[6,7]quinazolin-4-ones were likewise prepd. from 2-mercapto-3-phenylbenzo[6,7]quinazolin-4-one and the appropriate alkyl or arylalkyl halides. The 2,3-disubstituted derivs. were prepd. as follows. Benzo[6,7]aceanthranil (1 mole) (m. 169-70.degree., prepd. by refluxing 3 hrs. 18 g. II with 125 ml. Ac2O and leaving the mixt. overnight at room temp.) in dry C6H6 or xylene was treated with 1 mole of the appropriate primary amine or substituted hydrazine and the mixt. refluxed 6-10 hrs. The crude reaction product, obtained after treatment with 10% NaOH was purified by column chromatog. over Al2O3 using C6H6 or CHCl3 as eluent to yield 60-65% 2-methyl-3-substituted amino- and hydrazinobenzo[6,7]quinazolin-4-one. 2-Mercapto-3-phenylbenzo[6,7]quinazolin-4-one (V) was prepd. either by heating 2 hrs. at 180.degree. an intimate mixt. of 3 g. II and 2.2 g. pnenylthiourea or by refluxing 18 hrs. 5.5 g. II and 4 ml. phenyl-isothiocyanate in 100 ml. EtOH. The latter procedure gave better yields. V yielded the corresponding 2-alkyl, arylalkyl, or dialkylamino-alkylthio deriv. on treatment with appropriate alkyl, arylalkyl, dialkylaminoalkyl halides in the presence of alc. NaOH. 2-Alkylthio-3-phenylbenzo[6,7]quinazolin-4-one was dethionated with Raney-Ni in boiling iso-PrOH to give 3-phenylbenzo[6,7]quinazolin-4-one. Hydrolysis of the same alkylthio compd. with 6N HCl furnished 3-phenylbenzo[6,7]quinazoline-2,4-dione. Thionation of 2,4-dihydroxybenzo[6,7]quinazoline (VI) with P2S5 in C5H5N

gave 2-oxobenzo[6,7]quinazoline-4-thione (VII), m. >310.degree. (HOAc). Attempts to prep. 2-hydroxy-4-ethylthiobenzo[6,7]quinazoline by treating VII with EtI in the presence of NaOEt gave VI. Following I were prepd. (given R, R1 and m.p.): SH, COPh, 202-3.degree.; SH, H, 330.degree.; SEt, H, 221-2.degree.; N-methylpiperazino, H, 277-9.degree.; N-phenylpiperazino, H, 316.degree.; morpholino, H, 302-3.degree.; piperidino, H, 271-2.degree.; homopiperidino, H, 265.degree.; NH(CH2)2NEt2, H, 98-100.degree.; .beta.-(2-pyridyl)-ethylamino, H, 227-8.degree., NHNH2, H, >320.degree.; NHNHPh, H, 278-9.degree.; Me, Ph, 134-5.degree.; Me, o-MeC6H4, 159-60.degree.; Me, p-ClC6H4, 173-4.degree.; Me, (CH2)2NEt2, 97-9.degree.; Me, .beta.-pyrrolidyl ethyl, 111-12.degree.; Me, (CH2)2Ph, 159.degree.; Me, p-BrC6H4, 211-12.degree.; Me, homopiperidyl, 158-9.degree.; Me, CH2C6H3Cl2 (m,p), 189-90.degree.; Me, 4'-pyridyl, 220.degree.; Me, 2'-tetrahydrofurfuryl, 154-5.degree.; Me, NH2, 186-7.degree.; Me, p-diethylamino-o-methylphenyl, 199-200.degree.; Me, .beta.-(2-pyridyl)ethyl, 129-30.degree.; Me, 2'-(6-methyl)pyridyl, 174-5.degree.; SH, Ph, 330.degree. (decompn.); SEt, Ph, 190-1.degree.; S-CH2Ph, Ph, 180-2.degree.; H, Ph, 219-20.degree.; OH, Ph, 189-90.degree.; and S-(CH2)2-NEt2, Ph, 145-6.degree.. Some of the compds. exhibited central nervous system depressant activity at high dosage.

IT **21314-30-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 21314-30-7 CAPLUS

CN Benzo[g]quinazolin-4(3H)-one, 3-benzoyl-2-mercapto- (8CI) (CA INDEX NAME)



L14 ANSWER 41 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1969:11671 CAPLUS
DN 70:11671
TI Preparation of quinazoline, benzoxazine, and benzothiazine derivatives by
reaction of anthranilamides with thiophosgene
AU Wagner, Guenther; Rothe, Lothar
CS Pharm. Inst., Karl-Marx-Univ., Leipzig, Fed. Rep. Ger.
SO Zeitschrift fuer Chemie (1968), 8(10), 377-8
CODEN: ZECEAL; ISSN: 0044-2402
DT Journal
LA German
GI For diagram(s), see printed CA Issue.
AB 2-H2NC6H4CONHPr-iso treated with CSCl2 and Et3N in CHCl3 gave 2-SCNC6H4CONHPr-iso, which on heating gave 2-thioxo-3-isopropyl-1,2,3,4-tetrahydroquinazolin-4-one. 2-Me-NHC6H4CONHR (R = alkyl) treated with CSCl2 and Et3N gave I, which in acid media gave II. Alk. treatment of I gave III.
IT **13906-05-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 13906-05-3 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



L14 ANSWER 42 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1968:477225 CAPLUS
DN 69:77225
TI Synthesis of thioquinazolone derivatives as antimalarials and ataractic agents
AU Chaurasia, M. R.
CS Banaras Hindu Univ., Varanasi, India
SO Agricultural and Biological Chemistry (1968), 32(6), 711-14
CODEN: ABCHA6; ISSN: 0002-1369
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB A series of 6-iodo-2-alkylthio-3-organo-4(3H)-quinazolones of general formula I was prepd. by alkylating the Na salts of the corresponding 6-iodo-2-thioxo-3-substituted quinazoline-2,4(1H,3H)-diones, prepd. by previously published methods. For example, 15.76 g. 3-benzyl-6-iodo-2-thioxo-quinazoline-2,4-(1H,3H)-dione was added to 5.00 g. NaOH in 50% aq.

EtOH, the mixt. stirred until soln. was complete, 6.15 g. iso-PrBr added,
and the soln. stirred 1 hr. at 23-5.degree., cooled to 0.degree., and filtered, and the residue was washed with water and dried to give I (R = iso-Pr, R1 = PhCH2), m. 233.degree. (EtOH). I (R = HO2CCH2) were prepd. from ClCH2CO2Na. [TABLE OMITTED] The I prepd. are tabulated.

IT **19857-32-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 19857-32-0 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-6-iodo-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



L14 ANSWER 43 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1968:427375 CAPLUS
DN 69:27375
TI Some 6,8-dibromo-S-substituted-2-mercapto-3-aryl(or alkyl)-4-quinazolones
AU Bhargava, P. N.; Chaurasia, M. R.
CS Banaras Hindu Univ., Varanasi, India
SO Journal of Medicinal Chemistry (1968), 11(2), 404-5
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB I (R = alkyl or aryl, R1 = p-xylyl, Bu, iso-Pr, allyl) were prepd. by condensing 3,5-dibromoanthranilic acid with alkyl or aryl isocyanates, followed by treatment with alkyl halides. None of the compds. showed activity against Plasmodium gallinaceum in chicks.
IT **18730-39-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 18730-39-7 CAPLUS
CN 4(1H)-Quinazolinone, 6,8-dibromo-2,3-dihydro-3-(phenylmethyl)-2-thioxo-(9CI) (CA INDEX NAME)



L14 ANSWER 44 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1968:114543 CAPLUS
DN 68:114543
TI Antitubercular 6-methoxy-2-mercaptoquinazolin-4-ones
AU Murav'eva, K. M.; Arkhangel'skaya, N. V.; Shchukina, M. N.; Zykova, T. N.;
Pershin, G. N.
CS Nauch.-Issled. Khim.-Farmatsevt. Inst. im. Ordzhonikidze, Moscow, USSR
SO Khimiko-Farmatsevticheskii Zhurnal (1967), 1(8), 29-31
CODEN: KHFZAN; ISSN: 0023-1134
DT Journal
LA Russian
GI For diagram(s), see printed CA Issue.
AB A soln. of 1.67 g. 5-methoxyanthranilic acid (I) and 1.79 g. p-EtOC6H4SCN in 60 cc. abs. EtOH was refluxed 4.5 hrs. to give 70% II [R1 = H, R2 = p-EtOC6H4(A)] (IIa), m. 338-9.degree. (decompn.) (Me2NCHO). I, m. 147-8.degree. (benzene), was prepd. in 80.2% yield by hydrogenation of 0.0235 mole 5-methoxy-2-nitrobenzoic acid in 120 cc. MeOH over Raney Ni at 20-5.degree.. II (R1 = Pr, R2 = A), m. 156.5-7.5.degree., was obtained in 86% yield by stirring 0.001825 mole IIa, 0.00585 mole NaOH (90% aq. soln.), and 0.00228 mole PrBr 1 hr. at 20-30.degree.. Similarly prepd. were the following II (R1 = A) [R2, m.p. (EtOH) and % yield given]: iso-Pr, 143 0-3 5.degree., 31.1; Bu, 151-2.degree., 80; iso-Bu, 163-4.degree., 70; amyl, 125.5-6.5.degree., 83; isoamyl, 164.5-5.0.degree., 80; hexyl, 124-5.degree., 99; heptyl, 105-6.degree., 74; PhCH2, 159.0-9.5.degree., 70. II (R1 = H, R2 = Bz) (IIb), m. 183-4.degree., was obtained in 85% yield by treating 0.0177 mole 4,2-MeO(HO2C)C6H3NHCSNHBz (III) with 100 cc. concd. H2SO4. III, m. 197.degree. (decompn.) (EtOH), was prepd. in 89.6% yield by refluxing 0.021 mole I and 0.02 mole benzoylthiocyanate in 30 cc. abs. EtOH 1 hr. II (R1 = R2 = H), m. 295-6.degree. (decompn.), was obtained in 86% yield by treatment of 4.9 g. IIb with 3 g. NaOH in 50 cc. 50% aq. EtOH 24 hrs. Prepd. were the following II (R2 = H) [R1, m.p. (EtOH) and % yield given]: H, 183-4.degree., 85; H, 295-6.degree. (decompn.), 86; Me, 234-5.degree., 70; Et, 203-4.degree., 99; Pr, 194-5.degree., 85; Bu, 188-9.degree., 95; iso-Bu, 202-3.degree., 82; amyl 173-4.degree., 87; isoamyl, 179.5-80.5.degree., 98; hexyl, 159.5-60.0.degree., 90; heptyl, 158-9.degree., 82; PhCH2, 213-14.degree., 79; CH2:CHCH2, 184-5.degree., 75; CH2CO2H, 203-4.degree. (decompn.), 99.
IT **18216-31-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and antitubercular activity of)
RN 18216-31-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-benzoyl-2-mercapto-6-methoxy- (8CI) (CA INDEX NAME)



L14 ANSWER 45 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1968:105150 CAPLUS
DN 68:105150
TI New 6-bromo-2-(S-substituted-thio)-3-aryl(or alkyl)-4-quinazolones
AU Bhargava, Prithwi N.; Lakhan, R.
CS Banaras Hindu Univ., Varanasi, India
SO Current Science (1967), 36(21), 575-7
CODEN: CUSCAM; ISSN: 0011-3891
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB 5-Bromoanthranilic acid (11.9 g.) was treated with 6 ml. PhNCS in 50 ml. abs. EtOH at reflux for 4 hrs. to give 75% I (R = H, R' = Ph), m. 325.degree. (decompn.). The following I (R = H) were similarly prepd. (R', % yield, and m.p. given): o-MeC6H4, 80, 313.degree.; m-MeC6H4, 85, 309.degree.; p-MeC6H4, 80, 320.degree. (decompn.); m-ClC6H4, 95, 299.degree.; p-ClC6H4, 88, 319.degree.; o-MeOCH6H4, 80, 279.degree.; p-MeOC6H4, 90, 304.degree.; p-EtOC6H4, 85, 322.degree. (decompn.); Me, 80, 273.degree.; Et, 75, 245.degree.; Bu, 70, 238.degree.; PhCH2, 70, 233.degree.. I (R = H, R' = Ph) (8.5 g.) was added to 5 g. NaOH in 85 ml. 50% aq. EtOH, stirred, filtered, treated with 4 ml. MeI, and stirred for 1 hr. to give 60% I (R = Me, R' = Ph), m. 214.degree.. The following I (R = Me) were similarly prepd. (R', % yield, and m.p. given): o-MeC6H4, 67, 156.degree.; m-MeC6H4, 70, 169.degree.; p-MeC6H4, 59, 238.degree.; m-ClC6H4, 62, 171.degree.; p-ClC6H4, 45, 236.degree.; o-MeC6H4, 55, 158.degree.; p-MeOC6H4, 90, 207.degree.; p-EtOC6H4, 53, 234.degree.; Me, 75, 168.degree.; Et, 65, 138.degree.; Bu, 50, 106.degree.; PhCH2, 68, 126.degree.. Also prepd. were I (R = Et) (R', % yield, and m.p. given): Ph, 50, 152.degree.; o-MeC6H4, 75, 114.degree.; m-MeC6H4, 70, 135.degree.; p-MeC6H4, 90, 180.degree.; m-ClC6H4, 75, 172.degree.; p-ClC6H4, 60, 185.degree.; o-MeOC6H4, 55, 134.degree.; p-MeOC6H4, 80, 154.degree.; p-EtOC6H4, 65, 153.degree.; Me, 85, 108.degree.; Et, 50, 83.degree.; Bu, 45, 76.degree.; PhCH2, 95, 98.degree.; and I (R = Pr) R', % yield, and m.p. given): Ph, 60, 175.degree.; o-MeC6H4, 67, 99.degree.; m-MeC6H4, 85, 148.degree.; p-MeC6H4, 92, 146.degree.; m-ClC6H4, 64, 172.degree.; p-ClC6H4, 69, 185.degree.; o-MeOC6H4, 55, 121.degree.; p-MeOC6H4, 75, 165.degree.; p-EtOC6H4, 61, 134.degree.; Me, 65, 84.degree.; Et, 70, 82.degree.; PhCH2, 64, 81.degree..
IT **18009-18-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 18009-18-2 CAPLUS

L14 ANSWER 46 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1967:104980 CAPLUS
DN 66:104980
TI Syntheses of heterocycles. LXXXIX. Reactions of isatoic anhydride with derivatives of urea and thiourea
AU Kappe, Thomas; Steiger, Wilfried; Ziegler, Erich
CS Univ. Graz, Graz, Austria
SO Monatshefte fuer Chemie (1967), 98(1), 214-18
CODEN: MOCHAP
DT Journal
LA German
GI For diagram(s), see printed CA Issue.
AB cf. CA 66, 104884v. Isatoic anhydride (I) reacted with urea derivs., in a molten state at 150-90.degree. (method A), or in HCONMe2 (method B), to give the following 2,4-dioxotetrahydroquinazolines (II) (R, method, % yield, and m.p. given): H, A, 92, 350.degree.; Me, A, 71, 230-2.degree.; Bu, A, 76, 155-7.degree.; cyclohexyl, A, 70, 270-1.degree.; PhCH2, A, 88, 226-8.degree.; Ph, B, 75, 281-3.degree.; Et, A, 37, 195.degree.. Similarly from I and thiourea were prepd. the following 2-thiono-4-oxotetrahydroquinazolines (III) (same data given): H, B, 50, 281-2.degree.; Et, A, 32, 244-7.degree.; Bu, A, 65, 171-2.degree.; cyclohexyl, B, 58, 270-1.degree.; PhCH2, A, 95, 253-5.degree.; Ph, A, 60, 305-8.degree.; o-tolyl, A, 67, 253-5.degree.; p-tolyl, B, 48, 310-12.degree..
IT **13906-05-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 13906-05-3 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)



L14 ANSWER 47 OF 47 CAPLUS COPYRIGHT 2003 ACS
AN 1965:82549 CAPLUS
DN 62:82549
OREF 62:14670g-h,14671a-b
TI Synthesis of some S-substituted 2-mercapto-3-aryl-4-quinazolones
AU Bhargava, Prithwi Nath; Ram, Phulgan
CS Hindu Univ., Banaras, India
SO Bull. Chem. Soc. Japan (1965), 38(3), 342-4
DT Journal
LA English
AB A series of S-substituted 2-mercapto-3-aryl-4-quinazolones (I) was prepd.
as possible antimalarials from o-H2NC6H4CO2H (II), aryl isothiocyanates, and alkyl halides, m-ClC6H4NCS (15 g.), 15 g. II, and 150 cc. abs. EtOH refluxed about 2 hrs. gave the corresponding 2-mercapto-3-aryl-4-quinazolone (3-aryl group, % yield, and m.p. given): m-ClC6H4 (III), 90, 292.degree.; p-ClC6H4, 90, 320.degree.; p-BrC6H4, 90, 320.degree.; o-MeOC6H4, 75, 265.degree.; p-MeOC6H4, 80, 275.degree., p-EtOC6H4, 90, 335.degree.; PhCH2, 75, 248.degree.; 1-C10H7, 70, 266.degree.. III (7.5 g.) added with stirring to 5 g. NaOH in 85 cc. 50% aq. EtOH, filtered, and
stirred 1 hr. with 4 cc. EtI yielded 70% 2-ethylthio-3-(m-chlorophenyl)-4-
quinazolone, m. 124.degree. (EtOH). ClCH2CO2Na and III (equimolar amts.) in aq. alkali shaken 6 hrs. and acidified with dil. HCl yielded 75% 2-carboxymethylthio-3-(m-chlorophenyl)-4-quinazolone, m. 180.degree. (EtOH). Similarly were prepd. the following 2-substituted 3-(m-chlorophenyl)-4-quinazolones (2-substituent, % yield, and m.p. given): MeS, 86, 156.degree.; BuS, 70, 88.degree.; CH2:CHCH2S, 75, 178.degree.; CH2:CMeCH2S, 60, 94.degree.; PhCH2S, 80, 106.degree.; p-O2NC6H4CH2S, 70, 162.degree.. In the same manner were prepd. the I listed in the table. In the same manner were prepd. 2-methylthio-3-benzyl-
4-quinazolone (IV), 75%, m. 94.degree., 2-ETS analog of IV, 70%, m. 83.degree., and the 2-allylthio analog of IV, 70%, m. 93.degree.. 3-aryl
=, p-ClC6H4, p-BrC6H4, o-MeOC6H4, p-MeOC6H4, p-EtOC6H4; 2-substituent, % yield, m.p., % yield, m.p., % yield, m.p., % yield, m.p., % yield, m.p.; MeS, 90, 178.degree., 90, 208.degree., 88 , 134.degree., 84, 148.degree.,
90, 158.degree.; EtS, 80, 150.degree., 85, 146.degree., 72 , 114.degree.,
75, 170.degree., 85, 139.degree.; iso-PrS, 85, 152.degree., .., .., .., .., .., .., .., ..; BuS, 85, 113.degree., 85, 121.degree., 70 , 141.degree., 75, 122.degree., 80, 140.degree.; CH2:CHCH2S, 80, 137.degree., 85, 148.degree., 60, 98.degree., 70, 160.degree., 80, 152.degree.; CH2:CMeCH2S, 85, 134.degree., 80, 131.degree., .., .., 50, 113.degree. , 65, 134.degree.; p-O2NC6CH2S, 75, 218.degree., 75, 230.degree., .., .., 70 , 188.degree., 70, 186.degree.; HO2CCH2S, 80, 218.degree., 80 , 214.degree., .., .., 80, 182.degree., 80, 202.degree.; AmS, 75, 102.degree., .., .., .., .., .., .., .., ..;
IT **13906-05-3**, 4(3H)-Quinazolinone, 3-benzyl-2-mercapto-
(prepn. of)
RN 13906-05-3 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-3-(phenylmethyl)-2-thioxo- (9CI) (CA INDEX NAME)


H
N
S
N
CH2—Ph
O

=> d l1; d l3; d l7; d l9; d l11; d his
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 HAS NO ANSWERS
L3 STR



Structure attributes must be viewed using STN Express query preparation.

L7 HAS NO ANSWERS
L7 STR



Structure attributes must be viewed using STN Express query preparation.

L9 HAS NO ANSWERS
L9 STR



Structure attributes must be viewed using STN Express query preparation.

L11 HAS NO ANSWERS
L11 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE

Structure attributes must be viewed using STN Express query preparation.

(FILE 'STNGUIDE' ENTERED AT 19:49:11 ON 12 FEB 2003)
DEL HIS Y

FILE 'REGISTRY' ENTERED AT 19:50:40 ON 12 FEB 2003
L1 STRUCTURE UPLOADED
L2 0 S L1

FILE 'STNGUIDE' ENTERED AT 19:51:01 ON 12 FEB 2003

FILE 'REGISTRY' ENTERED AT 19:51:54 ON 12 FEB 2003
L3 STRUCTURE UPLOADED
L4 0 S L3

FILE 'STNGUIDE' ENTERED AT 19:52:15 ON 12 FEB 2003

FILE 'REGISTRY' ENTERED AT 19:52:47 ON 12 FEB 2003
L6 20 S L
L7 STRUCTURE UPLOADED
L8 2 S L7

FILE 'STNGUIDE' ENTERED AT 19:55:15 ON 12 FEB 2003

FILE 'REGISTRY' ENTERED AT 19:56:50 ON 12 FEB 2003
L9 STRUCTURE UPLOADED
L10 2 S L9

FILE 'STNGUIDE' ENTERED AT 19:57:15 ON 12 FEB 2003

FILE 'REGISTRY' ENTERED AT 20:01:16 ON 12 FEB 2003
L11 STRUCTURE UPLOADED
L12 6 S L1 OR L3 OR L7 OR L9 OR L11
L13 100 S L1 OR L3 OR L7 OR L9 OR L11 FUL

FILE 'CAPLUS' ENTERED AT 20:02:08 ON 12 FEB 2003

L14 47 S L13

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	211.23	675.23

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-30.60	-30.60

STN INTERNATIONAL LOGOFF AT 20:04:18 ON 12 FEB 2003